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 A major goal of the Leighton group is the synthesis of biologically relevant 
polyketide natural products. Among the most potent and chemically intriguing member of 
this class is spongistatin 1. This molecule has interested biologists and chemists for more 
than two decades. In this thesis, we report a highly practical and efficient synthesis of the 
EF fragment of spongistatin 1. This relied on the rapid introduction of a complex 
stereochemical array using double cross-metathesis/Sharpless asymmetric 
dihydroxylation reactions to quickly build the F-ring of spongistatin. The six contiguous 
stereocenters of the F-ring were established in just five steps. A new one-pot asymmetric 
strained-silane mediated allylation was developed that was greatly improved over 
previous methods in regards to practicality and substrate scope. This methodology was 
used to introduce the sensitive chlorodiene side chain. Finally, completion of the EF 
fragment led to the synthesis of a spongistatin 1 analog, using our previously developed 
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Chapter 1 Introduction 
 Marine-derived non-aromatic polyketide natural products are an intensely studied 
class of molecules due to their diverse structures and potent biological activity. The high 
degree of chemical complexity has intrigued synthetic chemists for decades. Furthermore, 
the pharmacological properties of many polyketides promise extremely potent 
therapeutics, often as anticancer drugs. However, despite the high degree of interest, their 
development as therapeutics is limited by very low natural abundance. Synthetic 
chemistry is currently the sole source of these exciting compounds. Therefore, the 
development of new and efficient strategies and methodologies for the construction of 
polyketides remains a worthy endeavor. 
 
Figure 1.1. Polyketides of interest to the Leighton group 
 The Leighton group has long been interested in the synthesis of polyketides and 
methodologies that enhance their facile synthesis.1–5 Because of the high degree of 
























































produce useful amounts of a given target. The methodologies developed have largely 
focused on the facile introduction of complex stereochemical arrays. These have been 
used to successfully synthesize epothilone B, dictyostatin and other compounds with a 
step count greatly reduced compared to previous efforts.5–7 This has enabled the Leighton 
group to develop analogs and constructs as potentially useful therapeutics. The focus of 
this thesis will be on the development of an efficient synthesis of the EF fragment of 
spongistatin 1 and the completion of a spongistatin 1 analog.  
1.1. Spongistatin 1 background 
1.1.1. Bioactivity and isolation of the spongistatins 
 Natural product collection initiatives in 1993 resulted in the independent isolation 
and characterization of three groups of similar macrolide polyketides, known as the 
spongistatins, cinachyrolides and the altohyrtins. These were collected from multiple taxa 
of marine sponge by the Pettit,8–11 Fusetani,12 and Kitagawa groups.13,14 It was 
hypothesized that a single group of symbiotic bacteria was responsible for their 
biosynthesis, due to the variety of sponges from which they were collected. Sponges, like 
most animals, do not possess the requisite biochemical machinery, polyketide synthases, 
needed to produce these natural products.15  
 In regards to structure, the natural products were all extremely similar except for 
discrepancies in stereochemistry at the E-ring ketal and the AB and CD spiroketals. 
Kitagawa was able to obtain 7.6 mg from 112 kg of wet sponge and despite the extremely 
small quantity isolated, used this to determine the circular dichroism and NMR properties 
to assign the relative and absolute stereochemistry.14 The first synthesis of these 
compounds, by Evans, confirmed that spongistatin 2 and altohyrtin C were identical.16–19 
 3 
Table 1.1. Average GI50 values for spongistatins 1-9 20 
 
 There are currently nine discovered members of the spongistatin family, with 
spongistatin 1 (1.1) being among the most active. The average GI50 values were 
determined by testing each compound against the National Cancer Institute’s panel of 60 
human cancer cell lines.9 The average value for spongistatin 1 is 0.13 nM, showing it has 
significantly more anti-proliferative activity than existing drugs like Taxol. It is worth 
noting that spongistatin 1 maintains excellent cytotoxicity against known chemoresistant 
cell lines.8 Additionally, it exhibits outstanding selectivity for the growth inhibition of 
cancer cells versus normal cells (10,000-fold).21 Key in vivo melanoma and ovarian 
xenograph models in mice show preliminary antitumor activity with minimal toxicity.22 
Spongistatin 1 is an anti-mitotic agent, having a mechanism of action shared with other 
marine polyketides.23 During cell division, or mitosis, cells use microtubules to mediate 

































































1 (1.1): R = Cl, R1 = R2 = Ac
2 (1.2): R = H, R1 = R2 = Ac
3 (1.3): R = Cl, R1 = H, R2 = Ac
4 (1.4): R = Cl, R1 = Ac, R2 = H







5 (1.5): R = Cl, R1 = H
7 (1.7): R = R1 = H
8 (1.8): R = H, R1 = Ac






increased activity against cancer cells, which generally reproduce at a faster rate than 
normal cells. Further studies suggest that spongistatin 1 shares a binding site with the 
Vinca alkaloids on β-tubulin.23,24 
1.1.2. SAR studies of spongistatin analogs 
 A few key conclusions can be derived from the nine members of the spongistatin 
family. Two critical structural elements are required for the most potent activity, the C5 
acetate (1.1 vs. 1.3, 1.5 vs. 1.9) and the C50 chloride (1.1 vs. 1.2, 1.5 vs. 1.7). The 
importance of the diene sidechain was also demonstrated by Paterson who showed that 
analog 1.10 was completely inactive, despite maintaining the rest of the molecule (Figure 
1.2).25 Therefore, we decided on the EF fragment of spongistatin 1, with the chlorodiene 
sidechain, as the target of our efforts. 
 
Figure 1.2. Paterson's truncated side chain analog 1.10 
 Additional studies have shown that the exact CD fragment is not critical to 
potency and may serve only as an architectural backbone to align the ABEF fragment. 






























analogs.26 Because of the complexity of spongistatin 1, multiple research groups have 
tested whether a simplified version would be biologically active and simplify the 
synthesis.27–30 Various analogs which contained only the EF or AB fragments were only 
weakly bioactive. However, Smith synthesized analog 1.11 which contained the ABEF 
fragment but replaced the CD portion with a simple alkyl linker (Figure 1.3).20,31,32 This 
had been designed using molecular modeling of spongistatin 1, trying to emulate the 
geometric arrangement of the molecule and align the ABEF fragment in the correct 
conformation. 
 
Figure 1.3. Smith ABEF analog 1.11 20 
 Analog 1.11 exhibited impressive (80-300 nM) inhibitory activity in a similar 
mechanism to spongistatin 1. Although this work provided the first proof-of-concept, the 
Leighton group, led by Dr. Linda Suen, embarked on the synthesis of an analog which 
would more closely resemble spongistatin 1 to retain more potency, yet at the same time 
























1.1.3. Redesign of the CD spiroketal 
 Following the promising results of the Smith CD-deleted analog, the Leighton 
group sought to design a new version of the CD fragment that would be easier to 
synthesize but retain comparable potency. The natural CD spiroketal is singly anomeric 
where only one of the C-O bonds is in the favored axial position in the spiroketal system 
(Figure 1.4). 
 
Figure 1.4. CD spiroketal conformations 
This is the contrathermodynamic product. Typically, spiroketals are synthesized by the 
simple acid-catalyzed cyclization of a dihydroxy ketone, however, this most commonly 
leads to the thermodynamically favored doubly anomeric product. Although the CD 
fragment may represent a unique scenario where the singly anomeric spiroketal is 
especially stable, it has still proven a historical challenge to furnish. Several clever 
solutions have been utilized to create the CD spiroketal.18,26,34–39 Many of these rely on 
the recycling and reequilibration of the undesired spiroketal or trying to kinetically 
control the spiroketalization and stopping partway. This represented a serious synthetic 
bottleneck. Additionally, it remained a sensitive functionality that could epimerize during 
the rest of the synthesis. 
 Therefore, the Leighton group envisioned spongistatin 1 analog 1.12 that has a 











spiroketal that would retain the same overall geometry as the natural product (Figure 1.5). 
This would orient the ABEF fragment in the appropriate position and maintain 
spongistatin 1’s high bioactivity. 
 Additionally, new methods in the asymmetric silane-mediated crotylation to join 
the AB and CD fragments were developed.3 This built on our previous synthesis of the 
AB fragment and large stockpile of material.40 This served as an excellent proof of 
concept that strained-silane allylation is a powerful way to enantioselectively join two 
highly functionalized fragments in natural product synthesis. This will be referred to as 
spongistatin 1 analog and the redesigned spiroketal will be referred to as CD*, with the 
asterisk referring to any material with a redesigned D ring. This effort was successful and 
a large quantity of the new ABCD* fragment was prepared. The natural EF fragment of 





Figure 1.5. Spongistatin 1 (1.1) and spongistatin 1 analog 1.12 
1.2. Previous syntheses of spongistatin 
 The astounding bioactivity of the spongistatin family immediately attracted the 
interested of the biomedical community. However, initial clinical testing was impeded by 
the severely limited supply of spongistatin from natural sources. Additionally, the 
synthetic community was interested to the spongistatins due to the opportunity to supply 
material for clinical studies and the unique synthetic challenge they posed. 
 Spongistatin 1 is a 42-member macrolactone with 24 stereocenters, two 
spiroketals and two heavily functionalized tetrahydropyran subunits. The three most 
challenging aspects are arguably the synthesis of the singly-anomeric CD spiroketal, the 
introduction of a sensitive chlorodiene side chain and the construction of the F-ring, a 
tetrahydropyran with five stereocenters. To this date, seven research groups have 
completed syntheses of spongistatin 1 and/or 2: Evans,16–19 Kishi,26,41 Smith,34,35,42–50 
Paterson,36,51–60 Crimmins,37,61–64 Heathcock,38,65–70 and Ley.39,71–74 However, in the 
pursuit of creating useful amounts of material, only the Heathcock and Smith groups have 



























































 As pioneered by the Evans group in the first reported synthesis of spongistatin 2, 
the Yamaguchi macrolactonization and Wittig olefination have been used to join the EF 
fragment with the ABCD fragment in all subsequent syntheses (Figure 1.6). In addition to 
the total syntheses, many more have been reported towards the EF fragment.75–83 This 
thesis will focus on the preparation of a novel EF fragment synthesis and therefore an 






Figure 1.6. Key disconnections of spongistatin 
1.2.1. Strategies towards the preparation of the F-ring 
 
Figure 1.7. EF fragment of spongistatin 1 
 The EF fragment contains 11 of the 24 stereocenters on spongistatin 1, nine of 
which reside on the two densely functionalized tetrahydropyran rings, E and F. Including 
the fully substituted F-ring, seven contiguous stereocenters are present on the molecule, 
presenting a serious challenge. Most of the synthetic effort on this fragment has been 
spent arranging the stereocenters on the F-ring and ensuring that it contains two handles 
to attach the chlorodiene sidechain and the E-ring. 
 The F-ring contains five stereocenters and requires at least one step mediated by a 






























1.1 R = Cl (spongistatin 1)






















state changes can easily stretch this into a very lengthy sequence. Setting multiple 
stereocenters sequentially through diastereoselective reactions serves to reduce the 
number of steps with using asymmetric reagents, but is often plagued by step-
inefficiency.  
  The first approach by Evans was to set the C40 and C41 stereocenters with an 
asymmetric Mukaiyama aldol using a chiral tin-bisoxazoline complex. (Scheme 1.1).18 
This was followed by a diastereoselective Mukaiyama aldol reaction. This was elaborated 
into glycal 1.18, which was posed to connect the pre-constructed E-ring and the sidechain 
by the later epoxidation of the glycal that will be discussed in a later section. This route 
involved a post-ABCD coupling introduction of the sidechain. This type of late-stage 
sidechain introduction was not utilized in later syntheses, due to the difficulties in the 




Scheme 1.1. Evan's route to F-ring glycal 1.18 
 The notable similarity of the F-ring to a sugar inspired the Heathcock group to 
utilize a chiral pool synthesis of F-ring 1.20 from commercially available sugar 1.19 in 11 
steps (Scheme 1.2).70,84 Many non-ideal steps were used to produce this F-ring. This 







































stereocenter was set next to a methyl ketone. Although the TIPS ether was not easy to 
elaborate into the sidechain, it did serve as an attachment point and enabled completion 
of the F-ring and side chain prior to coupling with the ABCD fragment. This methyl 
ketone was poised to participate in an aldol reaction that was used in multiple syntheses. 
 
Scheme 1.2. Heathcock's F-ring 1.20 
 The Paterson group made use of a diastereoselective boron-mediated aldol 
reaction to set another stereocenter of the F-ring.54 Starting with 1.21, which is derived 
from the commercially available Roche ester, and treating it with Cy2BCl and 
acetaldehyde gave 1.22 (Scheme 1.3). This was elaborated into enoate 1.23 which 
underwent Sharpless asymmetric dihydroxylation to set two more stereocenters. The 
cyclization to close the tetrahydropyran ring created a 1:1 mixture of epimers at C43 that 
had to be equilibrated. This was eventually elaborated into F-ring 1.25. This compound 
had protecting group consistency, six stereocenters had been set, and a methyl ketone and 
a more functionalized sidechain attachment point were present. This synthesis was 




















Scheme 1.3. Paterson's route to F-ring 1.25 
 Finally, the Smith group’s route to the EF fragment used a different E-F coupling 
strategy and required a slightly different F-ring. Two generations of this approach were 
used. The first route utilized the Petasis-Ferrier reaction of ester 1.26 to give ketone 1.27 
(Scheme 1.4A).46,85 This reaction entails the methylenation to an enol ether followed by 
Lewis acid promoted rearrangement. Following asymmetric α-hydroxylation using the 
Davis oxaziridine and isomerization of the methyl group at C40, this eventually led to 
aldehyde 1.28. This formed the cis-2,6-tetrahydropyran ring with the correct 
stereochemistry. 
 The second route utilized an organocatalytic aldol with propanal and subsequent 
Wittig olefination to form 1.30 (Scheme 1.4B).42 Sharpless asymmetric dihydroxylation, 
acid-catalyzed cyclization and protection gave lactone 1.31. This was reacted with cis-
hexenyl Grignard to form a hemiketal. The hemiketal was reduced with triethylsilane to 
give the desired cis-2,6-tetrahydropyran 1.32. The hexenyl handle was later cleaved and 










































Scheme 1.4. Smith group’s A) Petasis-Ferrier approach to 1.28. B) Organocatalytic aldol approach to 1.28 
 Finally, the Leighton group has recently reported a synthesis of the F-ring that 
made several key innovations that were used in this thesis work.86 We initially sought 
methyl ketone 1.33. This would provide the methyl ketone to perform an E-F coupling 
aldol and an ester to elaborate into the sidechain (Scheme 1.5). We envisioned this arising 
from 1.34 after decarboxylation of the β-keto ester and reduction of the C43 hemiketal, in 
analogy to previous precedent.87 Unraveling this shows the pseudo C2-symmetric tetraol 
1.35. This could come from dienone 1.36 via a double Sharpless asymmetric 
dihydroxylation and in turn from the cross-metathesis of 1.37 and 1.38.88 This cross-
metathesis asymmetric dihydroxylation (CMAD) sequence would quickly build 



























































Scheme 1.5 Retrosynthesis of the Leighton group's previous F-ring synthesis 
 Unfortunately the cross-metathesis between 1.37 and 1.38 was unsuccessful. 
However, we were able to able to furnish tetraol 1.40 from the CMAD sequence of diene 
1.38 and t-butyl acrylate (Scheme 1.6). This compound was protected as an orthoester 
that desymmetrized the molecule to give 1.41. This was elaborated to β-keto ester 1.42, 
which upon cyclization gave hemiketal 1.43. This was successfully reduced to the desired 
cis-2,6-tetrahydropyran and the reaction conditions also protected the free alcohol at C42 
and furnished the free carboxylic acid as 1.44. At this point, various protecting group 
manipulations and difficulties in transforming the methyl ester led to a successful but less 
than ideal synthesis of the F-ring. Nonetheless, it served to provide the starting point for 
















































Scheme 1.6. Partial 1st generation synthesis of the F-ring 
1.2.2. E-F coupling strategy and boron-mediated aldol reactions 
 The most common approach to the E-F coupling is a selective boron-mediated 
aldol between an F-ring methyl ketone and an appropriate E-ring precursor aldehyde.89 
This strategy was first used by Crimmins61 (Scheme 1.8) and followed by Paterson,54 
Heathcock,65 and Ley.73,74 Although some attempts had been made previously using a 
lithium enolate, these were plagued by poor selectivity.  
 The aldol reaction of the boron enolate of methyl ketones with aldehydes is well 
known to give the 1,5-anti aldol product when the methyl ketone contains a β-alkoxy 
group (Scheme 1.7). Excellent diastereoselectivity is observed when the β-alkoxy group 
is a benzyl ether or a para-methoxybenzyl ether. Replacing the β-alkoxy group with a β-
silyloxy group causes a complete loss of selectivity. This has been explained by DFT 
calculations on the preferred boat conformation of the transition state (Figure 1.8).90 The 



































































alkoxy oxygen. Silyl ether groups cannot achieve this hydrogen bond because the oxygen 
is electron-poor and the high steric bulk of the silicon substituents. This explains the lack 
of selectivity when a silyl ether chosen as the β-hydroxy protecting group. In the 
transition state leading to the disfavored 1,5-syn, there is a steric clash between the 
cyclohexyl group on boron and the rest of the molecule. This model is highly predictive 




Scheme 1.7. 1,5-anti aldol reaction 
 
 
Figure 1.8. Hypothesized boron-aldol transition state 
  
 The EF fragment 1.47 has a 1,5-anti relationship between C35 and C39. This 
would suggest that the aldol reaction would be selective for the desired product. The F-






























selectivity. Additionally the aldehyde contains both α and β stereocenters. This makes the 
entire system too complex to rationalize using a simple model. Fortunately, the 
combination of stereoelectronic factors favors the desired 1,5-anti product as long as the 
C38 hydroxy is protected as a benzyl ether. 
 The advantage of this strategy is setting the alcohol stereocenter at C35 and 
leaving C37 in the desired ketone oxidation state. This reaction gave aldol product 1.47, 
which was deprotected and cyclized with acidic methanol to furnish metal ketal 1.48 with 
the correct stereochemistry at C37 and exposed the C35 alcohol for protection (Scheme 
1.8). This strategy has proven to be reliable and selective and has been used with a 
variety of F-ring methyl ketones and E-ring aldehydes.  
 
Scheme 1.8. The Crimmins group’s aldol reaction to join the E and F fragments 
1.2.3. Chlorodiene sidechain installation approaches  
 The chlorodiene at C51 represents one of the most sensitive functionalities in 
spongistatin 1. In fact, its difficulty in handling most likely led many synthetic groups to 
initially target spongistatin 2, which contains a diene instead of the chlorodiene. This 
presents two challenges, the preparation of a chlorodiene and its introduction to an 









































 The synthesis of a functionalized chlorodiene that contains the C47 stereocenter 
and a functional group handle to attach directly to the F-ring proved to be difficult. This 
approach was used by Evans in his spongistatin 2 synthesis and adapted in later syntheses 
for spongistatin 1.19,62 Aldehyde 1.49 was obtained in multiple steps using Evan’s chiral 
oxazolidinone auxiliary and underwent an indium promoted allylation and dehydration to 
give the chlorodiene 1.51 (Scheme 1.9). This was transformed using Trost’s palladium-
catalyzed pi-allyl chemistry to obtain allyl stannane 1.52. This approach is highly 
convergent with regards to the respective complexity of the side chain and F-ring glycal. 
 
Scheme 1.9. Crimmins synthesis of allyl stannane 1.52 
  With the allyl stannane in hand, the introduction of the entire sidechain was 
accomplished (Scheme 1.10). After coupling the EF glycal to the CD and AB fragments 
to give 1.53, the glycal was stereoselectively epoxidized with DMDO to form 1.54. This 
was reacted with a Lewis acid and allyl stannane 1.52 to give 1.55. This set the final two 
stereocenters on the F-ring from the epoxidation and selection addition of the allyl 
stannane side chain. Although this is an effective approach to the introduction of the side 
chain, there are some drawbacks. Performing any chemistry on the ABCDEF coupled 
























stannane into the F-ring epoxide required more than a ten-fold excess of the allyl 
stannane that was not trivial to synthesize. 
 
Scheme 1.10. Sidechain addition by allyl stannane addition 
 Multiple syntheses of spongistatin 1 relied on the use of chlorodiene aldehyde 
1.60, for varying strategies. This sensitive compound has been synthesized using three 
different methods. Ley relied on the Johnson-Claisen reaction between orthoacetate 1.56 
and alcohol 1.57 to give 1.58 (Scheme 1.11A).73 The chloride was eliminated to give the 
enoate 1.59 which was reduced and reoxidized to give desired aldehyde 1.60. The second 
method used by Smith, allylated ethyl glyoxalate with 2,3-dichloropropene and aluminum 
to give 1.61 (Scheme 1.11B).91 This was mesylated and eliminated to give enoate 1.59, 
which was treated with the same reduction and oxidation procedure. The Paterson group 
used the Horner-Wadsworth-Emmons reaction of 2-chloroacrolein 1.62 which led 
directly to 1.59 (Scheme 1.11C). This was reduced with DIBAL and underwent a Swern 



































Scheme 1.11. Syntheses of aldehyde 1.60 by the A) Ley, B) Smith and C) Paterson groups 
 This aldehyde proved to be successful in Paterson’s EF fragment synthesis by 
treating it with the boron-enolate of a methyl ketone (Scheme 1.12).54 Methyl ketone 1.63 
and aldehyde 1.60 were successfully reacted with excellent selectivity to give 1.64. This 
compound required subsequent Lombardo methylenation of the ketone to furnish the 
alkene.92 This is undesired as this reaction uses a complex mixture of metals, including 
toxic lead, and can often be difficult to reproduce.  
 
Scheme 1.12. Boron-mediated aldol to install the chlorodiene sidechain 
 The Smith group utilized an umpolung approach with the appropriate nucleophile 
equivalent of the sidechain and an allyl halide (Scheme 1.13).42 Silyl cyanohydrin 1.65 
was deprotonated with LiHMDS and added to allyl iodide 1.66 and desilylated to give 






























































































enantioselectively with CBS catalyst to give the desired sidechain. This was an efficient 
method to introduce the sidechain although it suffered from the need for post-introduction 
manipulations and the need to introduce another stereocenter with a stoichiometric 
asymmetric reagent. With the knowledge of previous syntheses successes and failures, 
we were posed to design a new and efficient route to the EF fragment. 
 
Scheme 1.13. Umpolung approach to sidechain installation 
1.3. Development of spongistatin 1 as an anti-cancer therapeutic 
 Although the development of a highly efficient polyketide total synthesis 
highlights new synthetic methods and strategies, we were not simply interested in 
creating the most step-economical and efficient synthesis of spongistatin 1. Our ultimate 
goal is to develop a spongistatin 1 analog into an effective anti-cancer therapeutic. One 
approach to maximize the therapeutic potential of spongistatin 1 would be the use of 
targeted drug delivery, such as antibody drug conjugates (ADC). However, this will 
require the synthesis of multiple spongistatin 1 analogs. Each new linker design 
potentially requires a new analog. That is why having an extremely convergent and 

































developed ABCD* synthesis is amenable to derivation to create ABCD* linker analogs. 
An efficient synthesis of the EF fragment is critical to provide material to complete the 
spongistatin 1 analogs.  
 ADCs function by coupling a drug to an antibody whose specific antigen is 
expressed exclusively or preferentially on tumor cells. This would deliver the drug 
specifically to tumor cells. This has the effect of significantly reducing the amount of 
required drug and severely reducing off-target toxicity therefore lessening the side effects 
common in many chemotherapy regiments. After the antibody binds to its antigen, the 
entire ADC enters the cell by endocytosis. Inside the cell, the antibody is degraded by 
proteases, which leave the drug-linker construct intact.93 Additionally, the ADC drug 
delivery strategy has been shown to alleviate drug efflux by the tumor cell that is 
mediated by the multidrug resistance-associated p-glycoprotein transmembrane pump.94 
These multiple advantages have garnered the interest of chemists and biologists alike 
towards ADCs.  
 Despite the promising capabilities of ADCs, there are some challenges in their 
development. The drug molecule must have extremely high potency. Because of the cost 
and effort required to design and produce the antibody and linker a very powerful 
“warhead” must be attached. Additionally, the site of the linker on the drug must not be 
involved in the binding. Ideally, the linker site is located as far away as possible from the 
active binding pocket. Finally, the synthesis of the drug must be amenable towards the 
accommodation of the linker modification. This often presents a challenge in regards to 
functional group compatibility. Fortunately spongistatin 1 fulfills these criteria due to its 
 24 
extreme potency and the presence of the CD fragment that isn’t directly involved in 
binding and is amenable to chemical modification. 
 By combining a scalable synthesis of a spongistatin 1 analog coupled with an 
ADC strategy we hope to advance it as a potential anti-cancer therapeutic. However, this 
dictated that our synthetic strategy be cognizant of linker compatibility. Based on 
numerous SAR studies, we decided to initially target the C15 position as a potential 
linker site. This was chosen as this region is not critical to tubulin binding and was 
incorporated into our previous ABCD* synthesis. These ABCD* linker analogs would be 
equally as amenable towards the coupling of the EF fragment. The following chapters 
will describe the synthesis of the EF fragment of spongistatin 1, the synthetic innovations 
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Chapter 2 Synthesis of the F-ring of the spongistatins 
2.1. Introduction 
Many of the obstacles encountered in the synthesis of spongistatin 1 (2.1) are 
found on the EF fragment that is composed of two tetrahydropyran rings, each packed 
with complex stereochemical arrays. The EF fragment is defined as the portion of the 
molecule between C29-C51. The degree of stereochemical complexity is denser than the 
ABCD fragment and poses a significant challenge. The F-ring is composed of a fully 
elaborated tetrahydropyran ring with five contiguous stereocenters that are adjacent to 
two additional stereocenters. A large portion of our effort was spent designing a scalable 
synthesis of a suitable F-ring that could be connected with both the E-ring and the 
chlorodiene side chain. Previous SAR studies suggest that the EF fragment is crucial to 
activity, with the chlorodiene variant being most potent.20 Therefore, we targeted the 
natural spongistatin 1 EF fragment for synthesis to be combined with our existing 
ABCD* material to furnish spongistatin 1 analog. This chapter will describe our new 
synthesis of spongistatin 1’s F-ring. 
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Figure 2.1. Spongistatin 1 
2.1.1. Retrosynthetic analysis of the EF fragment 
One requirement of the synthesis of the EF fragment 2.3 was that it would be 
compatible towards coupling with the ABCD fragment 2.2. This entailed a Wittig 
reaction between C28 and C29 and a Yamaguchi macrolactonization between the C41 
alcohol and the C1 carboxylic acid. This disconnection was first used by Evans and then 
in all subsequent syntheses.19 This necessitated having a triphenylphosphonium salt at 
C29 and a hydroxyl group at C41 on EF fragment 2.3. This fragment can be seen as being 
composed of three distinct pieces: The F-ring, the E-ring and the chlorodiene sidechain 
(Scheme 2.1).  
Although there have been many approaches to introducing the sensitive 
chlorodiene side chain, as discussed, most suffer from step-inefficiency, yield or 
synthetic compatibility. We envisioned using an asymmetric allylation to join known 
chlorodiene aldehyde 2.4 with EF fragment silane 2.5 using Leighton group 
methodology.1,3 This silane would in turn come from the well-precedented aldol between 







































 The protecting group strategy bears comment. The coupling of the EF and 
ABCD fragment and end-game chemistry is known to be compatible with TES groups 
and the synthesis was designed to accommodate this.42 However, the protecting group 
strategy on the EF fragment prior to ABCD coupling was more complex and will be 
discussed. With these two disconnects in mind, we set out to design an F-ring that would 
be amenable to both an aldol and an allylation reaction. 
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Scheme 2.1. Retrosynthesis of spongistatin 1 and EF fragment 
2.2. Preparation of protected allylic alcohol methyl ketone 2.6 
 F-ring methyl ketone 2.6 is the most stereochemically dense fragment in 
spongistatin 1. The desired fragment contains six contiguous stereocenters, five of which 
are contained on the ring. We wanted to avoid the three major downfalls of previous 
syntheses: multiple steps that require the use of chiral catalysts or reagents, nonstrategic 
protecting group manipulation, and redox adjustments. The methyl ketone at C37 was 

















































































































functional handle at C43 would be. Two different functional handles were evnentually 
used. 
2.2.1. Retrosynthesis of F-ring methyl ketone 2.6 
 The strategy towards methyl ketone 2.6 relied on recognizing the element of C2- 
pseudosymmetry latent in the F-ring, as discussed in Chapter 1.86,95 Therefore we 
intercepted our previous synthesis using tetraol 2.10 (Scheme 2.2). This arises from the 
cross-metathesis asymmetric dihydroxylation (CMAD) sequence starting from 
commercially available diene 2.12. This would then undergo a desymmetrizing 
cyclization to set the methyl-containing stereocenter at C40. Whereas our first generation 
synthesis used an orthoacetate and benzyl protection to differentially protect alcohols and 
desymmetrize, we envisioned using a direct lactonization to arrive at lactone 2.9. This 
avoids complex protecting group manipulations and sets the C40 stereocenter. We then 
sought to install the C43 stereocenter via a methylenation and stereoselective 
hydroboration-Suzuki coupling sequence. This hydroboration reaction is known to give 
the desired cis-2,6-tetrahydropyran using a bulky borane.96 Following simple carbonyl 
manipulation at C37, we would arrive at F-ring methyl ketone 2.6. This sequence would 
allow us to install all six stereocenters in just five steps and protect all three alcohols with 




Scheme 2.2. Retrosynthesis of the F-ring 
2.2.2. Optimization of cross-metathesis to afford dienoate 2.11 
 Our previous synthesis of F-ring methyl ketone 2.6 utilized a double cross-
metathesis reaction of diene 2.12 with t-butyl acrylate (Scheme 2.3). This reaction needed 
to work on decagram scale for two reasons. First, we had sought to produce a highly 
scalable and efficient synthesis of the EF fragment. Second, in more practical terms, a 
large amount of dienoate 2.11 would be required to fully test all downstream chemistry 
and have enough material to complete the synthesis. However, the existing procedure had 
problems with the catalyst loading of Hoveyda-Grubbs 2 catalyst (HG-II) and reaction 
time.97,98 Although a catalyst loading of 2.25 mol % compares favorably to most uses in 
total synthesis, we sought to further lower it because on this large scale, the catalyst 
represents a significant hurdle. Additionally, the reaction time was seven days, with 
requisite addition of acrylate and catalyst each day, which proved to be highly 
inconvenient. 
 A report by the Slugovc group had shown that the cross-metathesis between alkyl 
terminal olefins and acrylates could be greatly improved in regards to catalyst loading 
and reaction rate by thoroughly removing oxygen and peroxides from the starting 






































provided a solution to our two key challenges in the improvement of the cross-metathesis 
reaction.  
 Combining diene 2.12 with a 20-fold excess of t-butyl acrylate with no additional 
solvent and adding the catalyst in three portions at 50 °C allowed the reaction to finish in 
just 5 hours with a 58% yield. Although this reaction results in a lower yield than the 
previous procedure, it is far more efficient in regards to reaction time. Additionally, the 
yield as a function of catalyst loading is illustrative. The original Tanis procedure results 
in 15.9 grams of desired product 2.11 per gram of HG-II, whereas the improved 
procedure results in 38.9 grams of 2.11 per gram of HG-II, a 2.5-fold increase. 
 
Scheme 2.3. Comparison of cross-metathesis procedures 
 Several technical aspects should be noted. The t-butyl acrylate must be passed 
through an alumina column to remove peroxides and thoroughly sparged with nitrogen 
gas to remove dissolved oxygen. Additionally, the reaction must be run using a dry-ice 
condenser to avoid losing the highly volatile starting material 2.12. Finally, the reaction 
must be run under a constant stream of nitrogen with an outlet to remove the ethylene 

























3 x 0.23 mol %
HG-II
50 °C, 5 h
58%
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pathways. This improved procedure was used to synthesize over 150 grams of dienoate 
2.11 over the course of the project. With an efficient reaction to make 2.11 in place, we 
utilized the existing Sharpless asymmetric dihydroxylation to produce large amounts of 
desired tetraol 2.10 (Scheme 2.4). This reaction gave a 4.5:1 mixture of 2.10:2.10a after 
chromatography and was used in subsequent reactions as a mixture. 
 
Scheme 2.4. Sharpless asymmetric dihydroxylation of 2.11 
2.2.3. Lactonizations of tetraol 2.10 
 Previous attempts to cyclize tetraol 2.10 into lactone 2.14 were largely 
unsuccessful. Numerous base-promoted lactonizations resulted in poor yields and very 
poor reproducibility. Therefore, we focused on an acid-mediated cyclization to afford 
lactone 2.14. This would obviate the need to differentially and selectively protect a 
tetraol, which proved to be a difficult task using acetals or silyl acetals. Previous reaction 
attempts using trifluoroacetic acid (TFA) were able to produce a 1:1 mixture of 2.13 and 



























Scheme 2.5. Acid promoted cyclizations of tetraol 2.10 
 However, upon additional of an alcoholic co-solvent (ethanol), the reaction led to 
the desired lactone 2.14. The lactone was recovered with the t-butyl ester intact. The 
addition of the ethanol likely tempered the acidity of the reaction to prevent ester 
cleavage. Most importantly, lactone 2.14 was obtained as a 10:1 mixture with its C40 
epimer epi-2.14. We hypothesize that ethanol provides a proton shuttle and nucleophile to 
render the cyclization reversible and allows generation of the thermodynamically favored 
product 2.14 that is the all-equatorial lactone (Figure 2.2). This product arises from 2.10. 
We hypothesize that the minor diastereomer of the tetraol 2.10a would give rise to 
lactones 2.14a and epi-2.14a. These sterically hindered products were not observed, 
suggesting that 2.10a does not reaction under these conditions. Therefore this reaction 
results in a partial resolution, upgrading the epimeric purity of the material substantially. 
With an efficient route to a suitable lactone, we tackled the difficult challenge of 

























































Figure 2.2 Cyclization of tetraols 2.10 and 2.10a 
2.2.4. Synthesis of benzyl lactone 2.15 
 Previous attempts at protecting 2.14 proved to be generally difficult for three 
reasons. The first is that the molecule contains three secondary hindered hydroxyls. In 
particular, the C41-C42 diol is challenging to protect because after one protecting group 
is installed, the second alcohol becomes more hindered. The second problem is that this 
molecule contains α-hydroxy and β-hydroxy esters that are intolerant of highly basic 
conditions. α-Hydroxy carbonyls tend to epimerize and β-hydroxy carbonyls tend to 
eliminate hydroxide to give a conjugated carbonyl compound. Finally, t-butyl esters are 
sensitive to highly acidic conditions. 
 We initially envisioned using the benzyl ether protecting group because of the 
literature precedent of a benzyl group at C38 leading to good results in the boron-
mediated aldol to join the E and F rings.61 We suspected that the classic sodium hydride 
and benzyl bromide conditions would be unsuitable due to aforementioned base 











































Scheme 2.6. Benzylation of triol 2.14 
 Various attempts at an efficient triple benzylation to provide 2.15 were plagued 
by a variety of problems. The Dudley reagent 2.17 is a neutral method for alcohol 
benzylation that operates through the thermal generation of benzyl cation as an ionic 
liquid.100 This reaction resulted in low yield (<30%) and incomplete conversion to the 
triply benzylated product. Additionally, large quantities of benzyl-related byproducts 
were formed which were extremely laborious to remove. Benzylation with benzyl 
trichloroacetimidate (BnTCAI) and triflic acid produced similar results.101  
 Finally, benzyl bromide and silver (I) oxide successfully produced 2.15 in 50% 
yield.42 However, the reaction was not scalable above 500 mg, which would be untenable 
moving forward. We suspect this was due to the heterogeneity of the reaction mixture 
that often does not translate to large-scale reactions. This reaction also produced traces of 
tetrabenzyl lactone 2.16 that was almost inseparable from the desired product. Forcing 
the reaction to favor 2.16 was unsuccessful, suggesting that the t-butyl ester was not 
compatible with the strongly electrophilic benzyl cation generated in this benzylation 
reaction. Therefore, we targeted another protecting group that will be compatible with the 

































2.2.5. Attempts to synthesize TES protected F-ring 2.21 
 Silyl groups are ubiquitous in organic synthesis for their ease of introduction and 
removal. Lactone 2.14 proved to be incompatible with the strongly basic or strongly 
acidic/electrophilic conditions required for the introduction of benzyl groups. Silyl ether 
groups are often installed using a weak amine base under more mild conditions. 
Pleasingly, TES protection of triol 2.14 gave lactone 2.18 in 79% yield (Scheme 2.7). 
This allowed us to test a key step in our retrosynthesis, the methylenation of a protected 
lactone. The Petasis reagent (Cp2TiMe2) was chosen over the Tebbe Reagent (AlMe3 + 
Cp2TiCl2) for its ease of use and synthesis, as well as its improved compatibility with 
acid-sensitive functional groups such as t-butyl ester and TES ether.102,103 This afforded 
enol ether 2.19 in 73% yield. Finally, we were in position to attempt the hydroboration-
Suzuki sequence to install the sixth stereocenter on the F-ring. 
 
 
Scheme 2.7. Attempts toward synthesis of tetrahydropyran 2.21 
 The hydroboration of acyclic enol ethers is typically unsuccessful due to the 
elimination of the resultant 1,2-oxoboron compound. This results in an olefin that can 














































well known to produce stable alkyl boron species that can be converted to either an 
alcohol via oxidation or engaged in a palladium-catalyzed Suzuki reaction with a suitable 
electrophile.96 Additionally, this reaction is highly stereoselective to favor the cis-2,6-
tetrahydropyran when bulky boranes are used such as 9-BBN (Figure 2.3).  
 
Figure 2.3. Hydroboration of enol ether 2.19 
 The reaction was monitored with 11B-NMR to observe the characteristic peak of a 
tri-alkyl borane, which was not observed. The reaction was extremely sluggish at 70 °C 
and 9-BBN decomposed at higher temperatures. It is common for the product of a Petasis 
methylenation to be contaminated with titanocene oxide byproducts even after 
precipitation with hexane, filtration and silica gel chromatography. Multiple purification 
methods were used to rigorously purify the enol ether, to no avail in the hydroboration.104 
The recalcitrance of enol ether 2.19 to undergo hydroboration was presumably due to the 
steric hindrance of the TES groups. This type of hydroboration is known on highly 
substituted sugar lactones when protected by the less bulky benzyl groups.105 Therefore, 
we sought to synthesize a lactone that we could successfully benzylate by changing the 
nature of the problematic C37 carbonyl. 
2.2.6. Attempts to synthesize a protected Weinreb amide 
 The Weinreb ketone synthesis is among the most effective methods for 























convert the C37 ester to a Weinreb amide and then to a ketone. The carbonyl 
manipulation step was therefore performed before the lactonization (Scheme 2.8). Tetraol 
2.10 was cleanly protected as its double acetonide to give diester 2.22 in 82% yield. This 
diester was then converted to diamide 2.23 in 71% yield by using the Weinreb amine salt 
and i-PrMgCl to generate a magnesium amide in-situ.107 This was cyclized with TFA and 
wet dichloromethane to give triol 2.24 in 71% yield that was not stable to silica gel 
chromatography. All benzylation attempts proved to be equally as ineffective as for the t-
butyl ester variant 2.14. Nonetheless, it was TES protected to cleanly give 2.25, albeit in 
poor yield (30%). 
 
 
Scheme 2.8. Synthesis of Weinreb amide 2.25 
 We expected that a Weinreb amide would not be an idle participant during the 
Petasis methylenation. Literature precedent reports that N,N-dialkyl amides are converted 
to enamines, which would be hydrolyzed upon work up to give ketone-containing enol 
ether 2.26.108 Instead, the reaction gave an equimolar mixture of the expected 2.26 and 
the demethoxylated amide 2.27 (Scheme 2.9). This was unexpected as there are no 

























































However, this is not entirely inexplicable as the N-O bond is weak and titanium is highly 
oxophilic. Attempts to change this ratio to favor the desired product were unsuccessful. 
At this point, discouraged by the seemingly intractable protecting group issues, we 
proposed a new synthesis of the F-ring.  
 
Scheme 2.9. Methylenation of 2.25 
2.3. Preparation of cis-hexenyl F-ring 2.28 
2.3.1. Retrosynthesis of F-ring methyl ketone 2.28 
 With a desire to quickly and efficiently synthesize the EF fragment we decided to 
use existing chemistry from the Smith route (Scheme 2.10).42 The cis-3-hexenyl fragment 
present on the left-hand side of the F-ring would eventually be converted into an allylic 
alcohol. Similarly, we envisioned introducing a hexenyl metal fragment to lactone 2.9, 
then silane reduction of 2.29.87 This would be followed by conversion to a Weinreb 

































Scheme 2.10. Retrosynthesis of methyl ketone 2.28 
2.3.2. Synthesis of TES protected methyl ketone 2.33 
 Initial attempts to introduce the cis-hexenyl fragment as a Grignard reagent were 
unsuccessful, likely due to the same steric bulk that inhibited the hydroboration reaction. 
Fortunately, the more reactive hexenyl lithium cleanly afforded the desired hemiketal 
2.30 in 87% yield (Scheme 2.11). 
 
 
Scheme 2.11. Synthesis of TES protected methyl ketone 2.33 
 Based on our previous synthesis of the F-ring, we suspected and then observed 































































































deprotection of the t-butyl ester. We thought this would be acceptable because a 
carboxylic acid is easily converted into to a Weinreb amide. However, we also observed a 
deprotection of the adjacent TES ether at C38. This was likely due to the extremely acidic 
effect of the proximal, newly created carboxylic acid.  
 This effect was ameliorated by the subsequent addition of triethylamine, which re-
silylated the alcohol using the excess TES-OTf and deprotonated the carboxylic acid, 
alleviating the proximal acid effect. However, upon workup and protonation of the 
carboxylate during isolation, the TES ether was simply deprotected again.  
 
Figure 2.4. Model α-silyloxy t-butyl esters 
 This phenomenon was confirmed by treating two α-silyloxy t-butyl esters 2.34 
and 2.35 with TES-OTf and triethylamine and observing the same desilylation to give 
mandelic acid and lactic acid, respectively (Figure 2.4). The carboxylate was instead 
protected in-situ as the methyl ester using TMS-CH2N2 before aqueous workup. This 
one-pot, three-step process produced methyl ester 2.31 in 37% yield. 1H-NMR coupling 
constants confirmed the geometry of the cis-2,6-tetrahydropyran. The yields for the 
conversion to the Weinreb amide 2.32 and subsequent methyl ketone 2.33 were both 
poor, which led to the conclusion that the extremely steric bulk of three TES groups 
interfered with the carbonyl manipulation steps as well.  
 In an attempt to improve the yield of the hemiketal reduction, a transesterification 










decided to revisit the benzyl protecting group with the knowledge that the acid-sensitive 
t-butyl ester may be switched with the potentially less problematic methyl version before 
the benzylation. 
2.3.3. Synthesis of methyl ketone 2.41 
 Being able to use the smaller benzyl protecting groups would likely alleviate the 
steric problems during the carbonyl manipulation towards the methyl ketone. 
Additionally, the benzyl group was expected to give excellent diastereoselectivity in the 
E-F aldol reaction. Because the initial lactonization of tetraol 2.10 was performed under 
alcoholic acid conditions, the natural conclusion was to combine the cyclization with the 
transesterification. However, as no transesterification to the ethyl ester was observed 
using TFA and ethanol, stronger conditions were required. TMS-Cl in methanol 
successfully afforded methyl ester 2.36 (Scheme 2.12). These particular conditions were 
chosen for two reasons. TMS-Cl, when heated in methanol produces anhydrous HCl in 
methanol. This is more convenient than using gaseous HCl and more reproducible than 
using commercial HCl in methanol that is difficult to titrate and purify. Additionally, 
upon reaction completion, the reaction mixture contains only volatile compounds 
(methanol, HCl and TMS-OMe) that can be easily removed by concentration. This 
proved to be necessary as 2.36 was not stable to silica gel chromatography; fortunately, it 
produced clean product.  
 We were exceedingly pleased to see that the benzylation of 2.36 with TriBOT 
2.42 (Figure 2.5) and triflic acid was reproducible, clean and scalable and gave 2.37 in 
62% yield over the two-step sequence.109 Additionally a mixture of doubly benzylated 
lactones was isolated in 9% yield that could be resubjected in similar conditions. TriBOT 
 52 
is a recently introduced analogue of BnTCAI that offers several advantages. It contains 
three reactive benzyl fragments per molecule and in this case, only 1.2 equivalents of 
TriBOT were required, which is only slight excess, improving atom economy over 
BnTCAI. TriBOT is a bench-stable crystalline solid that can be synthesized on large scale 
and stored indefinitely. Finally, the byproduct, cyanuric acid, can be removed by a simple 
wash with aqueous sodium hydroxide, which proved necessary to facilitate product 
purification. With an effective route to a benzyl protected lactone, we proceeded with the 




Scheme 2.12. Synthesis of benzyl protected methyl ketone 2.41 
 
Figure 2.5. TriBOT 2.42 
 Addition of cis-hexenyl Grignard afforded hemiketal 2.38.  Using the alkyllithium 
compound caused over-addition to the methyl ester. Cerium and zinc –ate complexes of 
the organomagnesium compound were not reactive enough at -78 °C and caused 
epimerization of the C38 stereocenter at 0 °C.  The four equivalents of the Grignard 
reagent were added slowly over five hours at -78 °C, lest it suffer from the same issues as 
the other metal species. The reduction with BF3OEt2 and triethylsilane afforded 
tetrahydropyran 2.39 in 58% over the two-step sequence with no side-reaction of the 
benzyl ethers or the methyl ester. Conversion to Weinreb amide 2.40 and methyl ketone 














































MeCN, -40 to 0 °C


















































protected version. Finally with an efficient route to the appropriately protected methyl 
ketone 2.41, we were ready to test the boron-mediated aldol to join the E and F 
fragments. This route was used to produce over 5 grams of 2.41 in an overall yield of 
8.9% in just 8 steps. Although the E-F coupling and downstream chemistry were 
moderately successful and will be discussed in Chapter 3, several issues caused us to 
revisit the original hydroboration-Suzuki route, using the new benzyl protected lactone. 
2.4. Preparation of methyl ketone 2.43 
2.4.1. Retrosynthesis of methyl ketone 2.43 
 Issues involving the inefficient and inconsistent conversion of the cis-3-hexenyl 
fragment into an allyl halide prompted a redesign of the methyl ketone. The sidechain 
would be brought in directly as a protected allylic alcohol to lactone 2.37, instead of an 
internal alkene. This would eliminate multiple problematic steps. Two strategies were 
devised. First, the allylic alcohol piece could be introduced to the lactone as an 
organometallic fragment and the resultant hemiketal 2.44 reduced (Scheme 2.13A). The 
second strategy was the most fruitful and was used to complete the synthesis of 
spongistain 1 analog; this was revisiting the original hydroboration-Suzuki route, albeit 
using the benzyl protected lactone 2.37 (Scheme 2.13B). 
 55 
 
Scheme 2.13. Retrosyntheses of methyl ketone 2.43: A) hemiketal reduction route B) hydroboration-
Suzuki route 
2.4.2. Synthesis of methyl ketone 2.43 via hemiketal reduction 
 Introduction of the appropriate allylic alcohol fragment relied on the synthesis of 
a suitable allyl halide. The Williamson ether synthesis with benzyl alcohol and 
Finkelstein halogen exchange of commercially available dichloride 2.46 provided allyl 
bromide 2.47 in 55% yield and 80% yield, respectively (Scheme 2.14).110 Attempts to 
lithiate or magnesate 2.47 were unsuccessful, likely due to the difficulty in generating 
allyl metal species. Instead, a one-pot Barbier process with zinc metal and TMS-Cl was 
used to generate hemiketal 2.44 cleanly. It should be noted that this reaction was 




























































Scheme 2.14. Attempts to synthesize methyl ester 2.48 
 Various combinations of Lewis acids, reductants and solvents were used in the 
attempt to reduce the hemiketal. TMS-OTf, TES-OTf and BF3OEt2 were used as Lewis 
acids. Triethylsilane and the more nucleophilic tributylsilane were used as reductants. 
Mixtures of dichloromethane, acetonitrile and propionitrile were used as solvents. 
Unfortunately, any reduction attempt led to a highly complex mixture that resulted in low 
yield and irreproducibility. We hypothesized that the oxocarbenium  / homoallylic cation 
intermediate was performing non-productive pathways. Nonetheless, a small amount of 
2.48 was obtained and successfully converted to methyl ketone 2.43. This led to the final 
synthesis of the methyl ketone, with proof that methyl ketone 2.43 could arise from 
methyl ester 2.48. 
2.4.3. Synthesis of methyl ketone 2.43 via hydroboration-Suzuki coupling 
 After changing the C37 t-butyl ester to a methyl ester, we needed to rethink the 
Petasis methylenation. Whereas t-butyl esters are inert to the Petasis methylenation, 
methyl esters are converted to enol ethers. We decided to use this to our advantage and 
functionalize C37 at the same time as C43. 
ClCl
1. NaH, BnOH, THF, 55%





































 Lactone 2.37 was transformed into enol ether 2.51 with a 55% yield (Scheme 
2.16). The typical Petasis methylenation uses at least two equivalents of the Petasis 
reagent because the by-product of the methylenation, titanocene oxide, can react with and 
consume the active titanium methylidene. However, due to the sluggish reactivity of the 
methyl ester, 3.5 equivalents were added. Under prolonged conditions, the newly created 
enol ether could undergo a side reaction with active titanium carbene, albeit slower than 
the desired reaction. Therefore, ethyl pivalate was added as a sink for excess reagent.104 
This reaction was scalable although multi-gram scale reactions gave a large amount of 
the single enol ether 2.45 as a byproduct. 
 Vinyl bromide 2.50 was synthesized from commercially available 2,3-
dibromopropene 2.49 in 52% yield (Scheme 2.15).  
 
Scheme 2.15. Synthesis of 2.50 
 We envisioned a selective hydroboration at the exocyclic enol ether, with the 
methyl enol ether being hydrolyzed to the desired methyl ketone as the conclusion of the 
reaction. The hydroboration of 2.51 was successful and selective for the more reactive 
enol ether. Following Suzuki coupling with 2.50, the reaction mixture was hydrolyzed 
with aqueous HCl in THF to yield methyl ketone 2.43 in 49% isolated yield, even though 











Scheme 2.16. Double methylenation route to 2.43 
 Because of the lower yields of the methylenation and hydroboration-Suzuki 
reactions, we synthesized enol ether 2.45 with 1.2 equivalents of Petasis reagent in a 
higher and more reliable yield of 75% (Scheme 2.17). This enol ether underwent the 
subsequent hydroboration-Suzuki reaction with a significantly higher 95% yield to 
provide methyl ester 2.48. After investigating multiple sources of palladium catalyst, the 
commercially available 3rd generation Buchwald precatalyst palladacycle with XPhos 
(XPhos Pd G3) performed the best.111 The methyl ester was converted to methyl ketone 












































Scheme 2.17. Synthesis of methyl ketone 2.43 
 
The finalized eight-step sequence to methyl ketone 2.43 was conducted on decagram 






































































Scheme 2.18. Final route to F-ring 2.43 
2.5. Summary and Outlook 
 In this chapter, we detailed the retrosynthesis of the EF fragment and the 
preparation of the F-ring. The protecting group strategy and high level of stereochemical 
density on this ring proved to be a major synthetic challenge. We believe that methyl 
ketone 2.43 provides the most effective and convenient way to combine the F-ring, E-
ring and chlorodiene sidechain.  The longest linear sequence of this route was 8 steps in a 
combined overall yield of 11.4%. This is a significantly more step-economical approach 
compared to other routes to an F-ring methyl ketone. All six stereocenters on methyl 
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Although the overall yield was moderate, it was very convenient and was used to produce 
over 15 grams of methyl ketone. At this point, with a significant stockpile of methyl 




















2.6. Experimental Procedures 
General Information. All reactions were carried out under an atmosphere of argon in 
flame-dried glassware with magnetic stirring and dry solvents unless otherwise indicated. 
Degassed solvents were purified by passage through an activated alumina column. t-
Butyl acrylate was purified by passage through an activated alumina column and 
degassed with N2. Et3N was distilled from CaH2. The synthesis of Cp2TiMe2, TriBOT 
and cis-3-hexenyl magnesium bromide were conducted as previously described, and all 
spectroscopic data were consistent with those reported for these compounds.105,109 Flash 
chromatography was performed with Silicycle SiliaFlash® P60 silica gel. pH 7 buffered 
silica gel was prepared by combining silica gel with 10% w/w dilute aqueous pH 7 
phosphate buffer. Thin-layer chromatography (TLC) was carried out on glass backed 
silica gel TLC plates (250 mm) from Silicycle; visualization by UV light, KMnO4 and/or 
ceric ammonium molybdenate (CAM). 1H NMR spectra were recorded on a Bruker 
AVIII 300 (300 MHz), AVIII 400 (400 MHz), or AVIII 500 (500 MHz) spectrometer and 
are reported in ppm, relative to residual protonated solvent peak (CDCl3, 7.26 ppm; C6D6, 
7.16 ppm). Data are reported as follows: (bs= broad singlet, s = singlet, d = doublet, t = 
triplet, m = multiplet, dd = doublet of doublets, ddd = doublet of doublet of doublets, ddt 
= doublet of doublet of triplets, td = triplet of doublets, q = quartet, p = quintet; coupling 
constant(s) in Hz; integration). Proton decoupled 13C NMR spectra were recorded on a 
Bruker AVIII 500 (126 MHz) spectrometer and are reported in ppm from CDCl3 internal 
standard (77.16 ppm). Infrared spectra were recorded on a Perkin-Elmer Spectrum Two 
(Diamond ATR) IR spectrometer.  Optical rotations were recorded on a Jasco DIP-1000 
 63 
polarimeter. Mass Spectroscopy Data was obtained on a Waters XEVO G2-XS QToF 
mass spectrometer. 
2.6.1. Preparation of tetraol 2.10. 
 
 To a solution of 3-methyl-1,4-pentadiene 2.12 (5.62 mL, 45 mmol, 1 equiv) in t-
butyl acrylate (135 ml, 0.9 mol, 20 equiv) was added Hoveyda-Grubbs 2nd Generation 
catalyst (65.6 mg, 0.105 mmol, 0.23 mol %). The flask was fitted with a dry-ice 
condenser under constant nitrogen flow and the reaction mixture was heated to 50 °C. 
After 1.5 h, an additional portion of the HG-II catalyst (65.6 mg, 0.105 mmol, 0.23 mol 
%) was added. After 1.5 h, an additional portion of the HG-II catalyst (65.6 mg, 0.105 
mmol, 0.23 mol %) was added. After 2 h, the reaction mixture was cooled to ambient 
temperature and concentrated. The residue was treated with toluene (100 mL) and the 
mixture was concentrated. The residue was purified by silica gel flash column 
chromatography (4% EtOAc/Hexanes) to yield dienoate 2.11 (7.55 g, 26.7 mmol, 58%) 
as a pale yellow oil. IR (thin film) 2977, 2933, 1713, 1614, 1392, 1318, 1153 cm-1. 1H 
NMR (500 MHz, CDCl3) δ 6.76 (dd, J = 15.7, 7.0 Hz, 2H), 5.73 (dd, J = 15.7, 1.3 Hz, 
2H), 3.17-3.08 (m, 1H), 1.47 (s, 18H), 1.20 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 165.9, 148.4, 123.2, 80.6, 38.5, 28.3, 18.6. HRMS (FAB+) calcd for 
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50 °C, 5 h
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 To a mechanically-stirred solution of K3Fe(CN)6 (148 g, 450 mmol, 6 equiv), 
K2CO3 (62.1 g, 450 mmol, 6 equiv), NaHCO3 (37.8 g, 450 mmol, 6 equiv) and 
CH3SO2NH2 (14.3 g, 150 mmol, 2 equiv) in H2 O (750 mL) was added a solution of 
(DHQD)2PHAL (3.00 g, 3.85 mmol, 0.05 equiv) in t-BuOH (500 mL). The mixture was 
cooled to 0 °C and K2OsO4 •2H2O (1.10 g, 3.00 mmol, 0.04 equiv) was added, followed 
10 minutes later by a solution of dienoate 2.11 (21.2 g, 74.9 mmol) in t-BuOH (250 mL). 
The bright orange suspension was stirred vigorously at 0 °C for 18 h. Solid Na2SO3 (94 g, 
749 mmol, 10 equiv) was added and the reaction mixture was stirred for a further 45 min. 
The layers of the cold reaction mixture were separated, and the aqueous layer was 
extracted with EtOAc (3 x 150 mL). The combined organic layers were stirred with solid 
NaCl, the resulting brine layer was removed. The organic phase was washed with 
additional brine (350 mL), dried over Na2SO4, filtered and concentrated. The residue was 
purified by silica gel flash column chromatography (50% EtOAc/Hexanes) to yield 
tetraol 2.10 (16.4 g, 46.7 mmol, 62%) as the major product of a 4.5:1 mixture of 
diastereomers as a colorless gum that solidified to a colorless solid on standing. This 
mixture was used as is in the next step, but for the purposes of characterization, an 
analytically pure sample was obtained by careful flash chromatography. [α]D21 –12.7º (c 
0.56, CHCl3). IR (thin film) 3473, 2978, 2934, 1716, 1394, 1288 cm-1. 1H NMR (400 

















8.4, 3.3 Hz, 1H), 3.99 (td, J = 8.9, 1.3 Hz, 1H), 3.55 (d, J = 8.5 Hz, 1H), 3.52 (d, J = 5.7 
Hz, 1H), 3.34 (d, J = 5.7 Hz, 1H), 3.22 (d, J = 9.1 Hz, 1H), 2.26-2.14 (m, 1H), 1.50 (s, 
18H), 1.07 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 173.0, 83.5, 83.3, 75.0, 
74.2, 72.2, 71.9, 40.0, 28.2, 13.1. HRMS (FAB+) calcd for [C16H30O8H+] requires m/z 
351.2013, found 351.2018. 
 
2.6.2. Preparation of enol ether 2.19 
 
 To a solution of tetraol 2.10 (1.21 g, 3.45 mmol) in CH2Cl2 (8 mL) and EtOH (7 
mL) was added TFA (2.60 mL, 34.5 mmol). The reaction was stirred for 24 h at rt, 
toluene was added and the reaction mixture was concentrated under reduced pressure. 
Purification by flash column chromatography (90% EtOAc/Hexanes) on silica gel gave 
lactone 2.14 as a pale oil (667 mg, 2.42 mmol, 70% yield). 1H NMR (400 MHz, CDCl3) 
δ 4.26 (dd, J = 10.4, 1.6 Hz, 1H), 4.18 (dd, J = 6.0, 1.6 Hz, 1H), 4.04 (dd, J = 9.9, 1.8 Hz, 
1H), 3.63 (td, J = 10.3, 2.6 Hz, 1H), 3.55 (d, J = 2.1 Hz, 1H), 3.30 (d, J = 6.0 Hz, 1H), 





































 Lactone 2.14 (500 mg, 1.80 mmol) was charged with dry pyridine (10 mL) and 
cooled to 0 ºC. TES-Cl (2.0 mL, 11.7 mmol) was added dropwise. The reaction mixture 
was heated to 60 ºC and stirred for 48 h. The reaction was slowly quenched by addition 
of NaHCO3 (sat. aq.) (25 mL). The reaction mixture was extracted with (3 x 5 mL). The 
combined organic layers were washed with brine (5 mL), dried over Na2SO4, filtered and 
concentrated. The crude product was placed under high vacuum for 3 h to remove 
pyridine. Purification by flash column chromatography (3% EtOAc/Hexanes) on silica 
gel gave TES ether 2.18 as a clear oil contaminated with TES2O (876 mg, 1.41 mmol, 
79% yield). 1H NMR (400 MHz, CDCl3) δ 4.67 (dd, J = 10.3, 2.4 Hz, 1H), 4.22 (d, J = 
2.4 Hz, 1H), 4.04 (d, J = 4.9 Hz, 1H), 3.70 (t, J = 4.6 Hz, 1H), 2.2-2.14 (m, 1H), 1.48 (s, 
9H), 1.11 (d, J = 7.1 Hz, 3H), 0.99 – 0.93 (m, 20H), 0.72 – 0.57 (m, 19H). 
 
 
  To a solution of TES ether 2.18 (250 mg, 0.404 mmol) in toluene (3.2 mL) in a 
sealed-tube pressure apparatus was added Cp2TiMe2 (912 mg of a 27.7% w/w solution in 
toluene, 1.21 mmol). The pressure apparatus was sealed and heated at 80 °C in the dark 
overnight. The reaction was cooled to rt and hexane (12 mL) was added to precipitate the 
titanocene oxide byproduct. The reaction mixture was filtered over Celite and 
concentrated. Purification by flash column chromatography (0% à 4% EtOAc/Hexanes) 
on silica gel gave enol ether 2.19 as a yellow oil (184 mg, 0.30 mmol, 73% yield). 1H 


















Hz, 1H), 4.22 (d, J = 3.1 Hz, 1H), 3.87 (m, 1H), 3.78 (m, 1H), 3.36 (m, 1H), 2.16 – 1.83 
(m, 1H), 1.51 – 1.47 (m, 9H), 1.01 – 0.91 (m, 32H), 0.65 (m, 20H). 
 
2.6.3. Preparation of methyl ketone 2.26 
 
 To a solution of tetraol 2.10 (1.2 g, 3.42 mmol) in CH2Cl2 (12 mL) and 2,2-
dimethoxypropane (8.4 mL) was added PPTS (858 mg, 3.42 mmol). The reaction mixture 
was heated at 60 °C overnight. NaHCO3 (sat. aq.) (20 mL) was added to quench the 
reaction. The layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 
10 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. 
Purification by flash column chromatography (10% EtOAc/Hexanes) on silica gel gave 
acetonide 2.22 as a clear oil (1.21 g, 2.81 mmol, 82% yield). 1H NMR (400 MHz, 
CDCl3) δ 4.43 (dd, J = 7.8, 2.7 Hz, 1H), 4.17 (m, 3H), 2.07 – 1.97 (m, 1H), 1.49 (s, 9H), 


































 Acetonide 2.22 (260 mg, 0.604 mmol) and NH(OMe)Me·HCl (1.18 g, 12.1 mmol) 
were suspended in THF (15 mL) and cooled to -40 °C. i-PrMgCl (9 mL, 2M in THF) was 
added over 30 min via syringe pump at this temperature. The reaction mixture was 
allowed to warm to rt overnight. The reaction was quenched by addition of NH4Cl (sat. aq.)  
(25 mL) and the layers were separated. The aqueous layer was extracted with Et2O (3 x 
10 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. 
Purification by flash column chromatography (50% EtOAc/Hexanes) on silica gel gave 
Weinreb amide 2.23 as a clear oil (187 mg, 0.462 mmol, 76% yield). 1H NMR (400 
MHz, CDCl3) δ 4.7 – 4.44 (m, 4H), 3.77 (s, 3H), 3.75 (s, 3H), 3.22 (s, 6H), 2.13 – 2.06 
(m, 1H), 1.45 – 1.36 (m, 12H), 0.99 (d, J = 7.0 Hz, 3H). 
 
 
 To a solution of Weinreb amide 2.23 (300 mg, 0.742 mmol) in wet CH2Cl2 (6 
mL) was added TFA (2.8 mL, 37.1 mmol). The reaction mixture was heated to 40 °C in a 
sealed vial for 2 h. The reaction mixture was concentrated, benzene (2 mL) was added 
and re-concentrated. To the crude mixture was added CH2Cl2 (3 mL), MeOH (1 mL) and 
K2CO3 (300 mg, 2.23 mmol) and shaken for 5 min. The solution was filtered and 
concentrated to give lactone 2.24 as a white solid (139 mg, 0.527 mmol, 71% yield). This 


























 Lactone 2.24 (120 mg, 0.186 mmol), DMAP (5 mg, .037 mmol) and imidazole 
(152 mg, 2.22 mmol) were dissolved in DMF (1 mL). TES-Cl (0.25 mL, 1.49 mmol) was 
added dropwise and the reaction was heated to 60 °C and stirred overnight. The reaction 
was quenched by the addition of MeOH (0.15 mL), stirred 10 min and diluted with 
NaHCO3 (sat. aq.) (5 mL). The aqueous reaction mixture was extracted with Et2O (4 x 4 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. 
Purification by flash column chromatography (0% à 20% EtOAc/Hexanes) on silica gel 
gave TES ether 2.25 as a pale oil (32 mg, 0.053 mmol, 30% yield). 1H NMR (400 MHz, 
CDCl3) δ 4.68 (m, 2H), 4.05 (d, J = 5.1 Hz, 1H), 3.83 – 3.66 (m, 4H), 3.38 – 3.15 (m, 




 To a solution of TES ether 2.25 (144 mg, 0.237 mmol) in toluene (2 mL) in a 
sealed-tube pressure apparatus was added Cp2TiMe2 (530 mg of a 28% w/w solution in 
toluene, 0.713 mmol). The pressure apparatus was sealed and heated at 80 °C in the dark 
overnight. The reaction was cooled to rt and hexane (10 mL) was added to precipitate the 




















































concentrated. Purification by flash column chromatography (0% à 20% 
EtOAc/Hexanes) on silica gel gave methyl ketone 2.26 (41 mg, 0.071 mmol, 30% yield) 
and amide 2.27 (46 mg, 0.081 mmol, 34% yield). 2.26: 1H NMR (400 MHz, CDCl3) δ 
4.41 (s, 1H), 4.29 (s, 1H), 4.14, (d, J = 2.3 Hz, 1H), 3.86 (m, 2H), 3.40 (t, J = 6.0 Hz, 
1H), 2.25 (s, 3H), 1.99 – 1.90 (m, 1H), 1.01- 0.92 (m, 30H), 0.71 – 0.57 (m, 18H). 2.27: 
1H NMR (400 MHz, CDCl3) δ 4.45 (s, 1H), 4.35 (s, 1H), 4.19 (s, 1H), 3.87 – 3.80 (m, 
2H), 3.38 (t, J = 6.6 Hz, 1H), 2.86 (d, J = 5.0, 3H), 1.95 – 1.86 (m, 1H), 1.04 – 0.87 (m, 
30H), 0.72 – 0.57 (m, 18H). 
2.6.4. Preparation of methyl ketone 2.33 
 
 
  To a -78 °C solution of cis-3-hexenyl iodide (678 mg, 3.23 mmol) in Et2O (12.5 
mL) was added t-BuLi (5 mL, 1.35M in pentane) drop wise. After stirring for 5 min, the 
reaction was allowed to warm to 0 °C over 30 min. The reaction mixture was cooled to -
78 °C and lactone 2.18 (1.00 g, 1.62 mmol) was added as a solution in Et2O (2 mL) and 
the reaction stirred for 1.5 h at this temperature. NH4Cl (sat. aq.)  (10 mL) was added to 
quench the reaction and the layers were separated. The aqueous layer was extracted with 
Et2O (2 x 5 mL). The combined organic layers were washed with NaHCO3 (sat. aq.) (5 mL), 
























chromatography (0% à 3% EtOAc/Hexanes) on silica gel gave hemiketal 2.30 as a 
mixture of diastereomers as a pale oil (983 mg, 1.40 mmol, 87% yield). 
 
 
 To a -78 °C solution of hemiketal 2.30 (100 mg, 0.142 mmol) and Et3SiH (0.25 
mL, 1.56 mmol) in CH2Cl2 (2.7 mL) was added TES-OTf (0.22 mL, .994 mmol) slowly. 
The reaction mixture was stirred at -78 °C for 10 min, 0 °C for 1 h, then rt for 1.5 h. The 
solution was cooled to 0 °C and Et3N (0.3 mL, 2.13 mmol) was added. The reaction was 
stirred at this temperature for 1 h. MeOH (0.5 mL) and TMS-CH2N2 (0.71 mL, 2M in 
Et2O) were added at 0 °C. The reaction mixture was stirred at this temperature for 30 min 
then at rt for 1 h, then diluted with NaHCO3 (sat. aq.) (5 mL) and EtOAc (5 mL). The layers 
were separated and the aqueous layer was extracted with EtOAc (3 x 5 mL). The 
combined organic layers were dried over Na2SO4, filtered and concentrated. Purification 
by flash column chromatography (0% à 3% EtOAc/Hexanes) on silica gel gave methyl 
ester 2.31 as a clear oil (34 mg, 0.053 mmol, 37% yield). 1H NMR (400 MHz, CDCl3) δ 
5.40 – 5.24 (m, 2H), 4.40 (d, J = 2.5 Hz, 1H), 3.72 (s, 3H), 3.40 – 3.21 (m, 3H), 2.95 
(ddd, J = 10.6, 8.4, 2.3 Hz, 1H), 2.12 (m, 1H), 2.01 (p, J = 14.5 Hz, 2H), 1.95 – 1.82 (m, 
2H), 1.76 – 1.65 (m, 1H), 1.51 – 1.39 (m, 1H), 1.34 – 1.19 (m, 1H), 1.02 – 0.85 (m, 33H), 




























 Methyl ester 2.31 (330 mg, 0.512 mmol) and NH(OMe)Me·HCl (225 mg, 2.30 
mmol) were suspended in THF (5.3 mL) and cooled to -40 °C. i-PrMgCl (2 mL, 2M in 
THF) was added over 30 min via syringe pump at this temperature. The reaction mixture 
was stirred at 0 °C for 1 h and at rt for 2 h. The reaction was quenched by the addition of 
NH4Cl (sat. aq.)  (8 mL) and the layers were separated. The aqueous layer was extracted 
with Et2O (3 x 5 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated. Purification by flash column chromatography (2% à 5% EtOAc/Hexanes) 
on silica gel gave Weinreb amide 2.32 as a clear oil (109 mg, 0.161 mmol, 32% yield). 
 
 
 To a -78 °C solution of Weinreb amide 2.32 (109 mg, 0.164 mmol) in THF (3 
mL) was added MeLi (0.15 mL, 1.6 M in Et2O). The reaction was stirred for 1 h at this 
temperature before another portion of MeLi (0.15 mL, 1.6 M in Et2O) was added. The 
reaction was stirred for 1 h at -78 °C and quenched by the addition of NH4Cl (sat. aq.)  (3 
mL). The layers were separated and the aqueous layer was extracted with Et2O (2 x 2 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. 


















































gave methyl ketone 2.33 as a clear oil (43 mg, 0.068 mmol, 41% yield). 1H NMR (400 
MHz, CDCl3) δ 5.56 – 5.07 (m, 2H), 4.12 (d, J = 2.4 Hz, 1H), 3.34 – 3.20 (m, 3H), 2.95 
(ddd, J = 10.3, 8.1, 2.3 Hz, 1H), 2.22 (s, 3H), 2.17 – 1.77 (m, 5H), 1.77 – 1.67 (m, 1H), 
1.50 – 1.37 (m, 1H), 1.02 – 0.92 (m, 33H), 0.72 – 0.59 (m, 18H). 
 
2.6.5. Preparation of methyl ketone 2.41 
 
 
 Tetraol 2.10 (20.83 g, 59.40 mmol) was charged with methanol (300 mL) and 
TMS-Cl (37.7 mL, 297 mmol) was added slowly in sealed-tube pressure apparatus. The 
vessel was sealed and the reaction mixture was heated at 65 °C for 18 hrs. The reaction 
mixture was concentrated under reduced pressure, toluene (150 mL) was added and 
concentrated again.  
To the crude mixture, TRIBOT (18.96 g, 47.52 mmol) and flame-dried MS 5Å 
(14.36 g) were added. 1,4-dioxane (585 mL) was added. Triflic acid (3.93 mL, 44.55 
mmol) was added and the reaction mixture was stirred for 1 hr. Additional TRIBOT 
(14.22 g, 35.64 mmol) was added and the reaction mixture was stirred for 4 hrs. 
Additional TRIBOT (14.22 g, 35.64 mmol) was added and the reaction mixture was 
stirred for another 18 hrs. 1M NaOH (aq.)  (45 mL) was added and stirred for 10 minutes. 
The reaction mixture was diluted with CH2Cl2 (450 mL) and filtered through Celite. The 































Na2SO4, filtered, and concentrated in vacuo to give the crude product as a yellow oil. 
Purification by flash column chromatography (5% à 10% à 20% à 30% 
EtOAc/Hexanes) on silica gel gave lactone 2.37 as a pale yellow oil (18.6 g, 36.8 mmol, 
62% yield over two steps) as well as a mix of doubly benzylated lactones (1.9 g, 4.58 
mmol, 9% yield). [α]D23 –43.6º (c 1.00, CH2Cl2). IR (ATR) 3029, 2876, 1754, 1496, 
1453, 1286, 1210 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.56 – 7.17 (m, 20H), 5.06 (d, J = 
11.2 Hz, 1H), 4.94 (d, J = 11.7 Hz, 1H), 4.80 (d, J = 11.1 Hz, 1H), 4.66 (d, J = 11.2 Hz, 
1H), 4.52 (d, J = 11.2 Hz, 1H), 4.42 (d, J = 11.7 Hz, 1H), 4.38 (dd, J = 10.4, 2.2 Hz, 1H), 
4.05 (d, J = 7.9 Hz, 1H), 4.03 (d, J = 2.2 Hz, 1H), 3.85 (s, 3H), 3.44 (dd, J = 9.8, 7.8 Hz, 
1H), 2.33 – 2.22 (m, 1H), 0.78 (d, J = 6.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
170.11, 169.66, 137.76, 137.31, 136.49, 128.89, 128.71, 128.66, 128.60, 128.57, 128.54, 
128.51, 128.32, 128.20, 128.09, 81.86, 80.42, 79.87, 75.41, 74.51, 74.36, 73.17, 52.71, 




 To a -78 °C solution of lactone 2.37 (11.5g, 22.7 mmol) in THF (120 mL) was 
added cis-3-hexenyl magnesium bromide (79 mL, 0.87M in THF) via addition funnel 
over 2 h. The reaction mixture was stirred at this temperature for 5 h. NH4Cl (sat. aq.)  (200 
mL) was added to quench the reaction and the layers were separated. The aqueous layer 






















brine (150 mL), dried over Na2SO4, filtered and concentrated. The crude hemiketal 2.38 




 Crude hemiketal 2.38 was charged with dry MeCN (225 mL) and Et3SiH (18.2 
mL, 114 mmol) and cooled to -40 °C. BF3OEt2 (11.1 mL, 90.8 mmol) was added 
dropwise, the reaction was warmed to 0 °C over 1 h and stirred at this temperature for 2 
h. The reaction mixture was quenched by the addition of NaHCO3 (sat. aq.) (300 mL) and 
EtOAc (100 mL). The layers were separated and the aqueous layer was extracted with 
EtOAc (3 x 100 mL). The combined organic layers were washed with brine (150 mL), 
dried over Na2SO4, filtered and concentrated. Purification by flash column 
chromatography (0% à 5% à 10% EtOAc/Hexanes) on silica gel gave methyl ester 
2.39 as a clear oil (7.26 g, 13.3 mmol, 58% yield over two steps). 1H NMR (400 MHz, 
CDCl3) δ 7.39 – 7.27 (m, 15H), 5.48 – 5.16 (m, 2H), 4.95 (d, J = 12.0 Hz, 1H), 4.90 (d, J 
= 10.9 Hz, 1H), 4.84 (d, J = 11.3 Hz, 1H), 4.62 (t, J = 9.9 Hz, 2H), 4.37 (d, J = 12.0 Hz, 
1H), 4.06 (d, J = 2.8 Hz, 1H), 3.80 (s, 3H), 3.41 (dd, J = 10.3, 2.8 Hz, 1H), 3.32 – 3.06 
(m, 3H), 2.22 – 1.90 (m, 4H), 1.85 – 1.75 (m, 1H), 1.57 (h, J = 4.5 Hz, 1H), 0.95 (t, J = 




























 Methyl ester 2.39 (3.36 g, 5.89 mmol) and NH(OMe)Me·HCl (1.72 g, 17.6 mmol) 
were suspended in THF (68 mL) and cooled to -20 °C. i-PrMgCl (17.3 mL, 2M in THF) 
was added over 30 min via syringe pump at this temperature. The reaction mixture was 
stirred at -15 °C for 30 min and at °C for 30 min. The reaction was quenched by addition 
of NH4Cl (sat. aq.)  (75 mL) and the layers were separated. The aqueous layer was extracted 
with EtOAc (3 x 75 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated. Purification by flash column chromatography (10% à 20% 
EtOAc/Hexanes) on silica gel gave Weinreb amide 2.40 as a clear oil (2.51 g, 4.17 mmol, 
71% yield). 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.11 (m, 15H), 5.45 – 5.21 (m, 2H), 
5.00 – 4.77 (m, 3H), 4.62 (dd, J = 11.0, 8.1 Hz, 2H), 4.34 (d, J = 12.1 Hz, 1H), 4.27 (d, J 
= 2.8 Hz, 1H), 3.58 (s, 3H), 3.48 (s, 1H), 3.32 – 3.22 (m, 4H), 3.22 – 3.02 (m, 2H), 2.33 – 
2.09 (m, 2H), 2.01 (dt, J = 14.8, 7.0 Hz, 3H), 1.86 – 1.72 (m, 1H), 1.65 – 1.51 (m, 2H), 
1.27 (s, 1H), 0.94 (t, J = 7.5 Hz, 3H), 0.74 (d, J = 6.5 Hz, 3H). 
 
 
 To a -78 °C solution of Weinreb amide 2.40 (7.22 g, 12.0 mmol) in THF (144 
mL) was added MeMgBr (8 mL, 3M in THF). The reaction mixture was stirred at 0 °C 






















































mL, 3M in THF) was added. The reaction mixture was stirred at 0 °C for 45 min. The 
reaction was quenched by addition of NH4Cl (sat. aq.)  (100 mL) and the layers were 
separated. The aqueous layer was extracted with EtOAc (3 x 75 mL). The combined 
organic layers were dried over Na2SO4, filtered and concentrated. Purification by flash 
column chromatography (10% EtOAc/Hexanes) on silica gel gave methyl ketone 2.41 as 
a clear oil (6.35 g, 11.4 mmol, 95% yield). 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.29 
(m, 15H), 5.39 – 5.19 (m, 2H), 4.94 – 4.75 (m, 3H), 4.61 (t, J = 11.3 Hz, 2H), 4.37 – 4.29 
(m, 1H), 3.80 (d, J = 2.4 Hz, 1H), 3.36 – 3.20 (m, 2H), 3.20 – 3.05 (m, 2H), 2.19 – 2.03 
(m, 1H), 2.03 – 1.92 (m, 3H), 1.88 – 1.75 (m, 1H), 1.60 – 1.45 (m, 2H), 0.93 (t, J = 7.5 
Hz, 3H), 0.66 (d, J = 6.5 Hz, 3H). 
2.6.6. Preparation of hemiketal 2.44 
 
 
 NaH (3.22 g, 80.5 mmol, 60% in mineral oil) was added to a flame-dried flask. 
Dry pentane (50 mL) was added and stirred for 5 min. The pentane was carefully 
removed by syringe. THF (110 mL) was added and the suspension was cooled to 0 °C. 
BnOH (8.5 mL, 82.4 mmol) was added and the reaction mixture was stirred at this 
temperature for 30 min before the addition of dry DMF (23 mL). The reaction mixture 
was refluxed at 80 °C for 30 min. 95 mL of this solution was transferred to an addition 
funnel and added to a 0 °C solution of dichloride 2.46 (5.5 mL, 47.5 mmol) in THF (31 
mL) over 2 h. The reaction was allowed to warm to rt overnight. The reaction was 
ClCl
1. NaH, BnOH, THF




quenched by the addition of H2O (100 mL). The solution was extracted with 
Et2O:pentane (1:1, 3 x 75 mL). The combined organic layers were washed with H2O (75 
mL) and brine (75 mL), dried over MgSO4, filtered and concentrated. Purification by 
flash column chromatography (0% à 2% Et2O/Hexanes) on silica gel gave allyl chloride 
as a clear oil which was used directly in the next step (5.09 g, 26.0 mmol, 55% yield). 
Spectroscopic data was consistent with those previous reported in the literature. 
 The resultant allyl chloride (5.0 g, 25.4 mmol) was mixed with LiBr (4.40 g, 50.8 
mmol) and TBAB (410 mg, 1.27 mmol) and stirred at 60 °C overnight. The mixture was 
diluted with Et2O:pentane (1:5, 50 mL) and filtered over silica gel to give allyl bromide 
2.47 as a clear oil (5.54 g, 23.0 mmol, 90% yield). Spectroscopic data was consistent with 
those previous reported in the literature. 
 
 
 Zn dust (156 mg, 2.38 mmol) was flame-dried under vaccum and covered with 
THF (6 mL). TMS-Cl (70 µL, .060 mmol) was added at rt and the mixture was stirred 15 
min. Allyl bromide 2.47 (287 mg, 1.19 mmol) was added and the mixture was stirred 
another 15 min. Lactone 2.37 (300 mg, 0.595 mmol) was added as a solution in THF (1.2 
mL) and the resultant mixture was stirred for 2 h. 0.1 M HCl (aq) (5 ml) was added. This 
was extracted with EtOAc (3 x 3 mL). The combined organic layers were dried over 

























2.6.7. Preparation of methyl ketone 2.43 
 
 
 Sodium hydride (3.07 g, 76.7 mmol, 60% in mineral oil) was charged with dry 
THF (300 mL) and cooled to 0 ºC. BnOH (6.34 mL, 61.39 mmol) was added dropwise 
and stirred 1 h at rt. The reaction was cooled to 0 ºC, and 2,3-dibromopropene 2.49 was 
added dropwise and the reaction was warmed to rt over 18 hrs. The reaction was 
quenched with NH4Cl (sat. aq.)  (300 mL), the layers separated and the aqueous phase was 
extracted with 3 x 75 mL Et2O. The combined organics layers were washed with brine, 
dried over Na2SO4, filtered, and concentrated. Purification by flash column 
chromatography (0% à 1% EtOAc/Hexanes) gave vinyl bromide 2.50 as a clear oil (7.30 
g, 32.17 mmol, 52%). IR (ATR) 3029, 2852, 1638, 1495, 1453, 1360, 1075, 897, 736, 
697. 1H NMR (500 MHz, CDCl3) δ 7.40 – 7.27 (m, 5H), 5.96 (s, 1H), 5.65 (s, 1H), 4.57 
(s, 2H), 4.14 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 137.66, 129.59, 128.61, 128.00, 
127.94, 117.92, 74.13, 72.22. 
 
 
 To a solution of lactone 2.37 (918 mg, 1.82 mmol) in toluene (15 mL) in a sealed-
tube pressure apparatus was added Cp2TiMe2 (5.77 g of a 24% w/w solution in toluene, 




























and heated at 80 °C in the dark overnight. The reaction was cooled to rt and hexane (100 
mL) was added to precipitate the titanocene oxide byproduct. The reaction mixture was 
filtered over Celite and concentrated. Purification by flash column chromatography (0% 
à 10% EtOAc/Hexanes) on silica gel gave enol ether 2.51 as a yellow oil (501 mg, 1.00 
mmol, 55% yield). 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.27 (m, 15H), 4.91 (d, J = 11.1 
Hz, 1H), 4.78 (dd, J = 14.0, 11.6 Hz, 2H), 4.65 (s, 2H), 4.58 (d, J = 11.1 Hz, 1H), 4.43 (d, 
J = 2.5 Hz, 1H), 4.38 (d, J = 11.9 Hz, 1H), 4.28 (d, J = 2.5 Hz, 1H), 3.98 (d, J = 8.1 Hz, 
1H), 3.86 (d, J = 2.1 Hz, 1H), 3.64 (s, 3H), 3.45 (dd, J = 10.4, 2.1 Hz, 1H), 3.19 (dd, J = 
9.9, 8.1 Hz, 1H), 2.24 – 2.09 (m, 1H), 0.70 (d, J = 6.6 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 159.39, 158.17, 138.58, 138.25, 137.76, 128.71, 128.53, 128.48, 128.44, 
128.25, 128.07, 127.98, 127.82, 127.79, 94.28, 84.72, 82.64, 82.34, 81.38, 76.53, 74.97, 
73.11, 72.20, 55.05, 37.55, 12.93. Low-Res MS  (ESI+) calcd for [C32H36O5SiNa+] 
requires m/z 523.25, found 523.55. 
 
 
 Enol ether 2.51 (1.70 g, 3.40 mmol) was charged with THF (19 mL) and cooled to 
0 °C. 9-BBN (13.6 mL, 0.5 M in THF) was added and the reaction was stirred at this 
temperature for 6 h. 3M K3PO4 (aq) (3.4 mL) was degassed and added to the solution 
which was stirred at rt for 20 min. In a separate flask, Pd(dppf)Cl2CH2Cl2 (277 mg, 0.34 




























mL). This solution was added drop wise to the borane mixture and stirred overnight at rt. 
NaHCO3 (sat. aq.) (15 mL) and H2O (150 mL) were added. The resultant mixture was 
extracted with Et2O (3 x 50 mL). The combined organic layers were concentrated. To this 
crude mixture were added THF (85 mL) and 1M HCl (aq) (5 mL) and this was stirred for 1 
h. NaHCO3 (sat. aq.) (80 mL) was added. The layers were separated and the aqueous layer 
was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated. Purification by flash column chromatography (5% à 
10% EtOAc/Hexanes) on silica gel gave methyl ketone 2.43 as a clear oil (1.06 g, 1.67 
mmol, 49% yield). [α]D22 –11.7º (c 1.00, CH2Cl2). IR (ATR) 3029, 2853, 1711, 1495, 
1453, 1352, 1072 cm-1.  1H NMR (500 MHz, CDCl3) δ 7.41 – 7.20 (m, 20H), 5.07 (s, 
1H), 4.94 – 4.83 (m, 3H), 4.78 (d, J = 11.9 Hz, 1H), 4.65 (d, J = 11.0 Hz, 1H), 4.60 (d, J 
= 10.9 Hz, 1H), 4.48 (d, J = 11.9 Hz, 1H), 4.42 (d, J = 11.9 Hz, 1H), 4.31 (d, J = 11.8 Hz, 
1H), 3.99 – 3.85 (m, 2H), 3.75 (s, 1H), 3.37 – 3.23 (m, 3H), 3.17 (t, J = 9.5 Hz, 1H), 2.69 
(d, J = 15.0 Hz, 1H), 2.19 (s, 3H), 2.12 – 2.03 (m, 1H), 0.64 (d, J = 6.5 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 212.90, 142.90, 138.53, 138.42, 138.24, 136.67, 128.88, 
128.71, 128.60, 128.57, 128.51, 128.46, 128.16, 127.95, 127.93, 127.87, 127.85, 127.58, 
113.92, 86.45, 83.26, 83.05, 83.02, 78.16, 75.62, 75.12, 73.72, 72.95, 71.93, 38.05, 35.45, 


























 To a solution of lactone 2.37 (10.10 g, 20.03 mmol) in toluene (167 mL) in a 
sealed-tube pressure apparatus was added t-BuOAc (1.35 mL, 10.02 mmol) and 
Cp2TiMe2 (20.8 g of a 24% w/w solution in toluene, 24.04 mmol). The pressure 
apparatus was sealed and heated at 80 °C overnight. The reaction was cooled to rt and 
hexane (600 mL) was added to precipitate the titanocene oxide byproduct. The reaction 
mixture was filtered over Celite and concentrated. Purification by flash column 
chromatography (5% à 10% EtOAc/Hexanes) on silica gel gave enol ether 2.45 as a 
yellow oil (7.35 g, 14.64 mmol, 75%). [α]D24 –39.1º (c 1.00, CH2Cl2). IR (ATR) 3029, 
2873, 1757, 1735, 1657, 1495, 1453, 1355, 1283, 1207, 1107 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 7.38 – 7.27 (m, 15H), 4.92 (dd, J = 11.4, 5.5 Hz, 2H), 4.77 – 4.71 (m, 1H), 4.66 
– 4.63 (m, 2H), 4.61 (s, 1H), 4.57 (d, J = 11.0 Hz, 1H), 4.39 (d, J = 11.9 Hz, 1H), 4.04 (d, 
J = 2.3 Hz, 1H), 3.98 – 3.92 (m, 1H), 3.85 (s, 3H), 3.67 (dd, J = 10.7, 2.3 Hz, 1H), 3.18 
(dd, J = 10.0, 8.2 Hz, 1H), 2.27 – 2.17 (m, 1H), 0.70 (d, J = 6.6 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 170.21, 156.64, 137.48, 137.11, 135.84, 127.88, 127.86, 127.59, 127.53, 
127.48, 127.33, 127.28, 127.20, 127.12, 127.01, 126.92, 126.88, 126.72, 93.73, 83.37, 
82.12, 80.22, 75.17, 74.16, 72.31, 72.16, 51.35, 36.23, 11.66. HRMS (ESI+) calcd for 





























 A solution of enol ether 2.45 (7.20 g, 14.34 mmol) in THF (48 mL) was charged 
with 9-BBN (1.84 g, 15.06 mmol) and stirred for 1 h at rt. The reaction mixture was 
heated at 45 ºC for 3 h and cooled to rt. 3M K3PO4 (aq) (12.0 mL) was degassed and added 
slowly to the borane solution which was stirred at rt for 20 min. In a separate flask, vinyl 
bromide 2.50 (3.58 g, 15.77 mmol) and XPhos Pd G3 (606 mg, 0.717 mmol) were 
dissolved in degassed DMF (72 mL). This solution was added dropwise to the borane 
mixture and the resultant mixture was stirred  at rt overnight in the dark. The reaction was 
quenched by addition of water (500 mL), the layers separated, and the aqueous phase 
extracted with Et2O (3 x 75 mL). The combined organic layers were washed with water 
(2 x 75 mL) and brine (1 x 75 mL). The combined aqueous layers were back-extracted 
with Et2O (1 x 100 mL). The combined organic layers were dried over Na2SO4, filtered, 
and concentrated. Purification by flash column chromatography (5% à 10% 
EtOAc/Hexanes) on silica gel gave methyl ester 2.48 as a colorless oil (8.78 g, 13.49 
mmol, 95% yield). [α]D25 –11.4º (c 1.00, CH2Cl2). IR (ATR) 3028, 2851, 1756, 1731, 
1651, 1602, 1495, 1453, 1358, 1283, 1207, 1164, 1072 cm-1. 1H NMR (400 MHz, 
CDCl3) δ 7.42 – 7.21 (m, 20H), 5.08 (s, 1H), 4.95 – 4.82 (m, 4H), 4.62 (dd, J = 12.6, 11.0 
Hz, 2H), 4.48 (d, J = 2.8 Hz, 2H), 4.34 (d, J = 12.0 Hz, 1H), 4.01 (d, J = 2.8 Hz, 1H), 3.92 
(q, J = 13.1 Hz, 3H), 3.70 (s, 3H), 3.40 (dd, J = 10.4, 2.9 Hz, 1H), 3.36 – 3.14 (m, 2H), 
2.63 (d, J = 15.0 Hz, 1H), 2.20 – 2.06 (m, 1H), 0.66 (d, J = 6.5 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 171.32, 143.05, 138.68, 138.48, 138.26, 136.97, 129.13, 129.01, 128.90, 
128.55, 128.53, 128.51, 128.39, 128.24, 128.12, 128.11, 127.98, 127.86, 127.83, 127.75, 
127.72, 127.49, 126.18, 126.16, 112.86, 86.67, 83.20, 82.06, 79.00, 76.56, 75.55, 75.14, 
 84 
73.34, 73.08, 71.94, 52.03, 41.75, 37.68, 34.78, 29.81, 12.27. HRMS (ESI+) calcd for 




 Methyl ester 2.48 (7.88 g, 12.11 mmol) and NH(OMe)Me·HCl (3.54 g, 36.33 
mmol) were charged with THF (140 mL) and cooled to -30 ºC. A solution of iPrMgCl 
(42.1 mL, 2M in THF) was added over 30 min by syringe pump at -30 ºC. The reaction 
mixture was allowed to warm to 0ºC and was stirred 45 min at this temperature. The 
reaction mixture was quenched by addition of NH4Cl (sat. aq.)  (100 mL) and the layers 
were separated. The aqueous layer was extracted with EtOAc (3 x 75 mL) and the 
combined organic layers were dried over Na2SO4, filtered, and concentrated. Purification 
by flash column chromatography (30% EtOAc/Hexanes) on silica gel gave Weinreb 
amide 2.52 as a white gum (6.15 g, 9.05 mmol, 75% yield). [α]D25 –19.2º (c 1.00, 
CH2Cl2). IR (ATR) 3028, 2852, 1681, 1495, 1453, 1359, 1208, 1071 cm-1. 1H NMR (400 
MHz, CDCl3) δ 7.37 – 7.21 (m, 20H), 5.09 (s, 1H), 4.96 (s, 1H), 4.93 – 4.82 (m, 2H), 
4.63 (t, J = 10.9 Hz, 1H), 4.32 (d, J = 12.0 Hz, 1H), 4.04 – 3.84 (m, 2H), 3.55 (s, 3H), 
3.49 (dd, J = 10.3, 2.9 Hz, 1H), 3.19 (s, 3H), 2.63 (d, J = 14.8 Hz, 1H), 2.28 – 2.07 (m, 
1H), 0.73 (d, J = 6.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δb143.41, 138.81, 138.60, 
138.34, 137.20, 129.13, 129.02, 128.94, 128.54, 128.53, 128.46, 128.38, 128.32, 128.16, 


























83.18, 75.42, 75.12, 73.53, 72.41, 71.99, 61.13, 41.76, 37.79, 34.81, 29.82, 12.40. HRMS 
(ESI+) calcd for [C42H49NO7Na+] requires m/z 702.3407, found 702.3406. 
 
 
 Weinreb amide 2.52 (6.15 g, 9.05 mmol) was charged with THF (110 mL) and 
cooled to -78 ºC. MeMgBr (5 mL, 3M in THF) was added and the reaction mixture was 
stirred 45 min at 0 ºC. The reaction mixture was re-cooled to -78 ºC. A second portion of 
MeMgBr (5 mL, 3M in THF) was added and the reaction mixture was stirred 30 min at 0 
ºC. The slurry was quenched by addition of NH4Cl (sat. aq.)  (100 mL), the layers separated, 
and the aqueous layer extracted with EtOAc (3 x 50 mL) The combined organic layers 
were dried over Na2SO4, filtered, and concentrated. Purification by flash column 
chromatography (10% EtOAc/Hexanes) on silica gel gave methyl ketone 2.43 as a 
colorless oil (5.46 g, 8.60 mmol, 95% yield).  
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Chapter 3 Synthesis of the EF fragment of spongistatin 1 and 
spongistatin 1 analog 
3.1. Introduction 
 With a steady supply of the F-ring in hand, we were excited to test out the two 
key disconnects of the EF synthesis, the E-F coupling aldol and the installation of the 
chlorodiene sidechain. Fortunately, the literature suggested that the boron-mediated aldol 
would be successful as discussed in Chapter 1.74 The E and F-rings were successfully 
joined using this method. A new strained-silane asymmetric allylation methodology was 
developed during attempts to introduce the chlorodiene sidechain. This was used to 
complete the synthesis of EF fragment. Additionally, it expanded upon previous complex 
fragment couplings by allylation, previously reported by the Leighton group.3,33 The EF 
fragment was synthesized in 18 steps using practical and reliable chemistry. Four more 
steps furnished a spongistatin 1 analog containing the previously described ABCD* 
fragment. 
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3.1.1. Retrosynthesis of the EF fragment 
 Our strategy to the EF fragment 3.1 remained the same as that proposed in 
Chapter 2. A more detailed view follows (Scheme 3.1).  
 
 
Scheme 3.1. Retrosynthesis of 3.1 
 We envisioned using a silane-mediated asymmetric allylation to join 3.3 and the 
chlorodiene aldehyde 3.2 to complete the side chain. This would set the final stereocenter 
and serve as a convergent route to the completed side chain. The allylic halide 3.3 that 
leads to a silane species would arise from the cyclization of aldol product 3.4, followed 
by protecting group manipulation and halogenation. Methyl ketone 3.5 and aldehyde 3.6 
































































3.2. Preparation of allyl bromide 3.23 from methyl ketone 3.15 
3.2.1. Synthesis of aldehyde 3.6 
 The first task towards examining the E-F aldol reaction was the preparation of 
aldehyde 3.6 (Scheme 3.2). Crimmins had previously used this aldehyde in his E-F 
coupling aldol.61 We decided to use the benzyl ether protecting group as on the F-ring to 
protect the right-hand side of the EF fragment, in order to simplify the deprotection 
strategy. However, we incorporated Leighton group strained-silane chemistry because of 
its advantages in simplicity and scalability. Selective mono-benzylation of 1,5-
pentanediol 3.7, followed by Swern oxidation gave aldehyde 3.9 in 87% over the two-
step sequence. This was subjected to a cis-crotylation with cis-crotyltrichlorosilane 3.11b 
and (R,R)-tridentate ligand 3.10 which afforded alcohol 3.12 in 79% yield.1 This was 
TES protected to give alkene 3.13 in quantitative yield. Finally, an Upjohn 
dihydroxylation, followed by cleavage with NaIO4 afforded aldehyde 3.6 in 73% yield. 
This process was chosen over ozonolysis due to the latter’s incompatibility with benzyl 
ethers. Indeed, this route was used to produce over 17 grams of material in a single pass. 





Scheme 3.2. Synthesis of aldehyde 3.6 
3.2.2. Synthesis of TBS ether 3.18 
 At this point, we had completed our first approach to the F-ring and had a 
multigram supply of methyl ketone 3.15. We first tried similar aldol conditions to the Ley 
group using Cy2BCl and triethylamine (Scheme 3.3).74 We were pleased to see that this 
reaction afforded β-hydroxy ketone 3.16 in 86% yield overall. However, the 
diastereoselectivity of this reaction was poor and gave only a 2.5:1 mixture of the desired 
C34-C35 syn product to the undesired anti product. This was surprising as examples 
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73% over 2 steps
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The results of a boron-mediated aldol that uses 1,5-stereoinduction are notoriously 
difficult to rationalize when the methyl ketone contains both α and β-oxygenated 
stereocenters.90 Attempts to correct this ratio by changing temperature, solvent and base 
were unsuccessful. Fortunately, the two diastereomers were partially separable by careful 
column chromatography. This reaction was scalable due to a recent innovation in the 
purification described by the Ley group.74 The use of Cy2BCl results in the production of 
Cy2BOH as a byproduct, which is extraordinarily difficult to remove from the desired 
product. Previous efforts to solve this problem utilized oxidation to destroy the boron 
compound, however this produces cyclohexanol that can be equally as difficult to 
remove. Pleasingly, simply stirring the crude material with silica gel after an aqueous 
workup and before silica gel chromatography successfully removes the boron residues. 
 Partially purified β-hydroxy ketone 3.16 was subjected to the acid-mediated 
deprotection and cyclization to give methyl ketal 3.17 in 91% yield.54 At this stage, the 
syn and anti diastereomers were easier to separate by column chromatography and syn 
3.17 was isolated cleanly. The overall yield of the syn diastereomer over this two-step 
sequence was 56%. This was protected as the TBS ether 3.18 in 81% yield. At this point, 
we had successfully joined the E and F rings and were ready to install the side chain after 




Scheme 3.3. Synthesis of 3.18 
3.2.3. Synthesis of allyl bromide 3.23 
 With the E and F-rings successfully joined, we now turned our focus to the 
elaboration of the EF fragment. While benzyl groups were necessary to impart selectivity 
on the boron-mediated aldol reaction and survive the acid-catalyzed E-ring cyclization, 
they now posed a problem.  There was no obvious method to remove the benzyl groups 
after installation of the chlorodiene side chain, so we decided to switch them to TES 
groups, analogous to the Smith route.42 The presence of the alkene precluded the use of 
simple hydrogenation with palladium. Reductive debenzylation with LiDBB afforded 
tetraol 3.19 in 82% yield (Scheme 3.4).114 Re-protection with TES-Cl gave TES ether 
3.20 in 93% yield. TES ether was selected as the protecting group in order to intersect 
with a known EF fragment, ensuring compatibility for downstream chemistry with the 































































 The next transformation was a one-pot ozonolysis and α-methylenation. 
Following ozonolysis and reductive quench with dimethyl sulfide, Eschenmoser salt was 
added with triethylamine to afford enal 3.21 in 54% yield.115 This reaction afforded a 
complex mixture containing an additional enal, which was identified as the trisubstituted 
alkene isomer. Additionally, this reaction proved difficult to reproduce on scale. Sudan 
III dye was used as a reaction progress indicator during the ozonolysis to attempt a more 
selective reaction, to no avail.116 Additionally, attempts to perform an alternative 
Lemieux–Johnson cleavage with OsO4 and NaIO4 were unsuccessful.117 Nonetheless, 
enal 3.21 was reduced with DIBAL to afford allyl alcohol 3.22 in 67% yield. This was 
smoothly transformed into allyl bromide 3.23 with an Appel reaction in 90% yield.118 
This represented our first synthesis of the desired side chain allylation precursor. 
However, the difficulties in the transformation of the cis-hexenyl side chain into a usable 
allyl bromide had led us to devise the second F-ring route towards methyl ketone 3.5. 
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Scheme 3.4. Synthesis of allyl bromide 3.23 
 
3.3. Preparation of allyl bromide 3.23 from methyl ketone 3.5 
3.3.1. Synthesis of polyol 3.27 
 The final F-ring synthetic approach was designed to alleviate the issues presented 
in the previous section. The same approach to the synthesis of a polyol was used as 
before (Scheme 3.5). The boron-mediated aldol between methyl ketone 3.5 and aldehyde 
3.6 was achieved in 84% yield and 11:1 dr to give 3.24. This was a notable improvement 
in diastereoselectivity over the previous aldol reaction (2.5:1 dr). This was a pleasant 
surprise as methyl ketones 3.15 and 3.5 are extremely similar. Separation of the syn and 

























































































ketal 3.25 in 70% yield. This was cleanly protected in 87% yield to give TBS ether 3.26. 
It should be noted that the next reaction required rigorous purification of 3.26 to remove 
any trace of 2,6-lutidine. 
 
 
Scheme 3.5. Synthesis of polyol 3.27 
 Debenzylation was performed to afford polyol 3.27 in 86% yield. At this stage, 
the material was notably obtained as a white solid. Therefore, this molecule was carefully 
crystallized by slow evaporation of a dichloromethane solution to provide X-ray 
crystallography quality material (Figure 3.1). This was crystallized by Dr. Dan Paley at 
the Shared Materials Characterization Laboratory. This crystal structure confirmed 10 of 
the 11 stereocenters on the EF fragment. At this point, we needed to transform polyol 















































































Figure 3.1 Molecular structure of 3.27 (one of two independent molecules shown). Blue, silicon; red, 
oxygen; black, carbon; white circles, hydrogen. C-H hydrogens and the minor positions of the disordered 
Si(tBu)Me2 group are omitted for clarity. 
3.3.2. Synthesis of allyl bromide 3.23 
 Polyol 3.27 posed a challenge in selectively functionalizing the five hydroxyl 
groups to eventually furnish 3.23. Fortunately, there was a difference in reactivity 
between the primary alcohols and secondary alcohols. We initially envisioned selectively 
brominating the allylic alcohol under Appel conditions and protecting the remaining four 
alcohols as TES groups. Unfortunately, this proved to be unfeasible. The primary alcohol 
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at C29 was more reactive than the allylic alcohol at C47 due to stereoelectronic factors, 
so the reaction resulted in 3.28, albeit in an inseparable mix with triphenylphosphine 
oxide (Scheme 3.6). Instead, we protected the C29 alcohol as a TES group to give 3.29 in 
42% yield. Unfortunately, the bromination of this compound was unsuccessful. 
 
 
Scheme 3.6. Attempted syntheses of 3.23 
  Finally, we devised a reliable route to 3.23 in four steps from polyol 3.27 
(Scheme 3.7). The polyol was per-silylated and the primary TES ethers were selectively 
removed with potassium fluoride to give diol 3.30 in 74% yield. The C29 hydroxyl was 
selectively re-silylated with TES-Cl in 97% yield to afford allyl alcohol 3.22. This step 
was much more selective between the two primary alcohols compared to 3.27, likely due 
to the increased steric bulk from the TES groups near the allylic alcohol at C47. 3.22 was 
brominated as before to give allyl bromide 3.23 in 90% yield. This highly non-polar 
product was trivial to separate from the triphenylphosphine oxide byproduct and was 
obtained in high-yield reactions. With more 3.23 in hand, we were ready to develop a 


























































Scheme 3.7. Synthesis of allyl bromide 3.23 
3.4. Development of a one-pot asymmetric allylation 
 The Leighton group has been a pioneer in the asymmetric allylation of carbonyl 
compounds using strained silicon reagents.1,4,119–122 Sequential developments have 
improved allylations in regards to reactivity and ease-of-use. Commercially available EZ-
crotyl reagents 3.31 require the isolation of a reactive silane complex by crystallization or 
air-free filtration and the use of an exogenous Lewis acid (Scheme 3.8A).4 This proves to 
be synthetically challenging and would require the formation and purification of an EF 
silane complex. This results in reduced yields especially on small scale. More recently 
however, former graduate student Dr. Linda Suen developed a methodology that does not 
require the isolation of a silane complex, using the tridentate ligand 3.10 and forming an 
in-situ silane complex with DBU and trichlorosilane 3.11 (Scheme 3.8B).1 Addition of an 
aldehyde yields the homoallylic alcohol 3.32 in excellent yield and enantioselectivity. 































































isolation of an organotrichlorosilane, thus limited the scope and synthetic ease of the 
allylation procedure. The Suen methodology was successfully used to couple the AB and 
CD* fragments in high efficiency.33 The AB trichlorosilane was generated via the 
hydrosilylation of a diene and produced a clean trichlorosilane without purification.40 
 
  
Scheme 3.8. Previously developed allylations by the Leighton group: A) EZ-crotyl, B) tridentate ligands 
 Inspired by the application of this methodology towards coupling complex 
fragments, the Leighton group endeavored to develop a generalized procedure for 
telescoping the formation of allylic trichlorosilanes into an enantioselective allylation 
reaction. The most common method to synthesize allylic trichlorosilanes is the Benkeser-
Furuya method followed by distillation or air-free filtration (Scheme 3.9).123,124 Filtration 









(R,R)-3.31a: R1 = R2 = H
(R,R)-3.31b: R1 = Me, R2 = H
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3.11a: R1 = R2 = H
3.11b: R1 = Me, R2 = H









impossible. It was hypothesized that the tridentate ligand 3.10 would be compatible with 
a wide variety of allylic trichlorosilanes, beyond the previously reported allyl and crotyl 
trichlorosilanes. 
 
Scheme 3.9. Benkeser-Furuya synthesis of organotrichlorosilanes 
 Therefore, we envisioned performing the Benkeser-Furuya reaction on an allyl 
halide and directly adding tridentate ligand 3.10 and base to generate the desired silane 
complex in-situ, followed by the addition of aldehyde to yield the product (Scheme 3.10). 
This method would be amenable to a much greater range of allyl halides, especially those 
that are too high molecular weight to distill including 3.23. Former post-doctoral fellow 
Dr. Kevin Williamson and graduate student Makeda Tekle-Smith pioneered this 
methodology. 
 
Scheme 3.10. One-pot allylation using strained silane chemistry 
3.4.1. Optimization of the one-pot procedure 
 The initial silylation of trans-crotyl chloride 3.33c into trichlorosilane 3.11c in 
dichloromethane was successful using copper (I) chloride and triethylamine (Scheme 




3.11a: R1 = R2 = H
3.11b: R1 = Me, R2 = H







3.33a: R1 = R2 = H
3.33b: R1 = Me, R2 = H
3.33c: R1 = H,  R2 = Me
Cl R1








ether as the solvent, generating a suspension. However, as previously shown in the 
optimization of asymmetric allylation methodology using tridentate ligand 3.10, the 
entire reaction mixture needed to be homogenous and therefore dichloromethane was 
used as the solvent as it can dissolve the generated ammonium salts. The success of the 
first step in the sequence was promising. 
 The next step was to test the complexation of (R,R)-3.10 with the generated 
trichlorosilane. Tridentate ligand and three equivalents of DBU were added and complex 
3.34 was observed. Finally, addition of hydrocinnamaldehyde 3.35 produced the desired 
homoallylic alcohol 3.36 in 34% yield using this unoptimized one-pot procedure. 
 
Scheme 3.11. One-pot allylation to form 3.36 
 The reaction conditions were optimized with regards to base, catalyst and allyl 
halide choice (Tables 3.1, 3.2). It was confirmed that the reaction worked best using allyl 
bromides and copper (I) bromide. Additionally, it was found that the reaction required 
triethylamine for the silylation step and DBU for silane complexation step. At this point, 























bromide 3.23. Following optimization, the substrate scope was significantly expanded to 
a wide variety of allyl bromides and aldehydes. 
Table 3.1. Optimization of the copper catalyst 
 
 
entrya halide catalyst catalyst 
loading 
yieldb 
1 Cl CuCl 5% 34% 




4 Br CuBr 5% 76% 
5 Br CuBr 10% 71% 
6 Br CuBr 20% 75% 
7 Cl CuBr 5% 27% 
 
aUnless otherwise noted, reactions were performed using 1 mmol allyl halide and 0.95 mmol 















 HSiCl3, CH2Cl2, 0 ºC
2. Tridentate Ligand (R,R)-3.10
DBU, CH2Cl2, 0 ºC to 23 ºC
3. cool to 0 ºC
add:






Table 3.2. Optimization of the base 
 
 







1 iPr2NEt 70% -- -- -- 
2 DBU 47% -- -- -- 
3 Et3N >95% -- -- -- 
4 Et3N >95% Et3N 62% 94% 
5 Et3N >95% DBU 80% 93% 
6e Et3N >95% DBU 82% 98% 
aUnless otherwise noted, reactions were performed using 1 mmol methallyl bromide and 0.95 mmol 
hydrocinnamaldehyde.  bDetermined by 1H NMR.  cIsolated yield. dEnantiomeric excess determined by 
HPLC analysis. ePerformed at –30ºC 
 
3.5. Preparation of model coupling product 3.38 
 We decided to try a model coupling reaction in order to troubleshoot the key side 
chain allylation, expecting three key challenges initially. The first was that allyl bromide 
3.23 was acid-sensitive because the TES groups. During the typical procedure for the 
one-pot allylation, the allyl bromide and trichlorosilane are dissolved in dichloromethane 
and added to a solution of triethylamine and copper (I) bromide. However, this would 
expose acid-sensitive 3.23 to the acidic trichlorosilane. A modified procedure was 
developed in which half of the triethylamine is added with the trichlorosilane and allyl 
bromide to prevent degradation. The second challenge was that chlorodiene 3.2 is very 
1. 5% CuBr, Base A (1.4 equiv), 
  Cl3SiH(1.2 equi.), CH2Cl2, 0 ºC
2.  Tridentate Ligand (R,R)-3.10
        Base B (3 equiv), CH2Cl2
                0 °C to 23 °C
3. cool to 0 ºC
    add:










unstable, so we wanted to test its stability under the reaction conditions. Finally, the 
allylation reactions are quenched with TBAF, which could remove the silyl groups on the 
EF fragment. 
3.5.1 Synthesis of allyl bromide 3.43 
 We sought a model compound that contained sensitive primary TES ether and a 
methallyl bromide. Compound 3.43 was selected. Commercially available alcohol 3.39 
was TES protected to give 3.40 in 94% yield (Scheme 3.12). This was epoxidized with 
mCPBA to give epoxide 3.41 in 75% yield.125 The epoxide was isomerized with LiTMP 
and Et2AlCl to give allyl alcohol 3.42. The crude product was subjected to an Appel 
bromination to give allyl bromide 3.43 in 30% over two steps.  
 
 
Scheme 3.12. Synthesis of 3.43 
3.5.2 Synthesis of aldehyde 3.2 
 Although chlorodiene aldehyde 3.2 is known in the literature and has been used in 
multiple spongistatin 1 syntheses,54,73,91 all but one synthesis exclude experimental details 
on how to produce this sensitive compound. The reported Paterson route relied on the 

































30% over 2 steps
Br
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2-chloroacrolein using chlorine gas proved to be non-reproducible.126 Therefore, we 
envisioned a new synthesis of aldehyde 3.2 which skipped this step. Commercially 
available 2-chloro-2-propen-1-ol 3.44 was treated under a Swern oxidation (Scheme 
3.13). The salts were crashed out with diethyl ether and the solution of 2-chloroacrolein 
underwent an air-free filtration and was treated with triethylphosphonacetate and 
NaHMDS. This avoids the isolation of 2-chloroacrolein and afforded ester 3.45 in 55% 
yield. The ester was reduced with DIBAL to give alcohol 3.46 in 74% yield. This was 
oxidized to give 3.2 in 89% yield and was used directly in the allylation reaction.  
 
 
Scheme 3.13. Synthesis of aldehyde 3.2 
 Allyl bromide 3.43 and aldehyde 3.2 were combined under the modified allylation 
conditions. The amount of TBAF3H2O added at -40 °C was carefully controlled. The 
reaction was successful and afforded 3.47 in 63% yield and 90% ee (Scheme 3.14). With 
































Scheme 3.14. Synthesis of 3.38 
3.6. Introduction of the chlorodiene side chain and completion of EF fragment 3.51 
3.6.1. Synthesis of allylation product 3.48 
 Initial observations during the reaction of 3.23 and aldehyde 3.2 showed the 
conversation to trichlorosilane was extremely sluggish at 0 °C (Scheme 3.15). Upon 
monitoring of the silylation step at room temperature, it was observed that the allyl 
bromide 3.23 was undergoing substantial decomposition. It was hypothesized that the EF 
allyl bromide might be too unstable under the reaction conditions. An EF allyl chloride 
variant might be a more suitable participant in this reaction.  
 
Scheme 3.15. EF side chain allylation reaction 
 However, as previously shown, the original trans-crotyl chloride gave much 
lower yields than the corresponding bromide.  This was initially puzzling as both allyl 
halides undergo the silylation and ligand complexation steps with excellent conversion. 
Therefore, the natural conclusion was that the allylation step was the difference and was 














































chain installation as well as substantially expand the substrate scope of the one-pot 
allylation methodology, conditions were optimized to enable chlorides as competent 
substrates.  The Denmark group has previously reported problems with the reaction 
between aliphatic aldehydes and allyltrichlorosilane. This was hypothesized to result 
from the formation of an unreactive chlorohydrin derived from the aldehyde. In this case, 
the rate of allylation was improved by the addition of tetrabutylammonium bromide 
(TBAB).127 
 The addition of TBAB significantly improved the yield of the one-pot allylation 
when using an allyl chloride. It was found that the allylation step required the presence of 
bromide ions, whether from the substrate allyl bromide or added as an exogenous 
bromide source. The Et3NHCl salts generated in the silylation step might form the 
unreactive chlorohydrin. This advance served to greatly expand the substrate scope of 
this methodology to include the more stable and readily available allyl chlorides, as well 
as improve the yield when using allyl bromides. Although the discovery of TBAB would 
serve critical to the eventual success of the EF side chain allylation, the reaction did not 
initially work when using the EF allyl chloride and TBAB. 
 Eventually, several key advancements enabled the reaction to succeed. Initial 
results in the reaction of 3.23 and 3.2, gave 3.48 in 62% yield as a single diastereomer 
(Scheme 3.16). As previously discussed, addition of TBAB was found to improve the 
allylation step regardless of whether an allyl chloride or allyl bromide was used. 
Additionally, the methyl variant of the tridentate ligand 3.49 was used. This less-hindered 
version was more reactive and gave comparable stereoselectivity. Most importantly, the 
addition of excess 2,6-di-t-butylpyridine was found to prevent acid-promoted 
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decomposition during the silylation. The E-ring methyl ketal is highly acid sensitive and 
was being degraded by the mild acid present during the one-pot allylation conditions. 
Although it was previously known that excess DBU or triethylamine would hinder the 
reaction, the extremely bulky 2,6-di-t-butylpyridine did not have this effect, instead only 
serving to successfully buffer the reaction. With this very promising result, we set out to 
redesign the allyl halide partner to reduce the overall step count. 
 
 
Scheme 3.16. Synthesis of 3.48 
3.6.2 Synthesis of EF fragment 3.53 
 Although the one-pot allylation was successful, the route to allyl bromide 3.23 
had undesired protecting group manipulations both before and after the side chain 
allylation. Multiple silyl protection and deprotection steps reduced the step-economy of 
the route to 3.23. We would also need to convert the primary TES ether at C29 after the 
side chain allylation into a triphenylphosphonium salt. This would require a three-step 
sequence of deprotection, halogenation and phosphonium salt formation. During the 










































that the reaction was fully tolerant of a non-allylic primary chloride present on the allyl 
halide. Therefore, we saw an opportunity to streamline our synthesis by performing a 
double chlorination of diol 3.30. This was achieved using carbon tetrachloride and 
triphenylphosphine to give dichloride 3.48 in 87% yield (Scheme 3.17). The C29 primary 
chloride could be converted directly to the Wittig salt in one step. 3.50 was subjected to 
the same allylation conditions as 3.23 and afforded 3.51 in 52% yield, 94% based on 
recovered starting material. While this represented an impressive yield for such a 
complex fragment coupling, we wanted to optimize the reaction to make better use of this 
precious late state material. 
 Contemporaneous work by Makeda Tekle-Smith on a one-pot asymmetric 
allylation using propargyl chloride yielded an important realization. This silylation was 
also very sluggish and it was found that trichlorosilane was evaporating from the reaction 
mixture before it was consumed. Portion-wise addition of extra trichlorosilane during the 
reaction enabled efficient conversion. This strategy was applied to the coupling of 3.50 
and 3.2 to solve the same problem. Additionally, the copper catalyst loading was 
increased to 25 mol % At this point, the allylation was optimized to give 3.51 in 71% 
yield, 94% brsm. TBS protection gave 3.52 in 90% yield. Finally, treatment with 
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triphenylphosphine and sodium iodide gave phosphonium salt 3.53 in 92% yield.54 
 
Scheme 3.17 Synthesis of Wittig salt 3.53 
 The route from methyl ketone 3.5 was used as the finalized version of the EF 
synthesis to give a few hundred milligrams of material. The synthesis of the EF fragment 
had a longest linear sequence of just 18 steps in 2% overall yield (Scheme 3.18). This 
represents the most step-economical synthesis of the EF fragment of spongistatin 1 to 
date. The two keys to this success were the rapid installation of the stereochemical array 
on the F-ring and the newly developed one-pot asymmetric allylation used to introduce 

































































































































































































































































3.7. Preparation of spongistatin 1 analog 3.58 
 With an ample supply of both ABCD* and EF fragments, Makeda Tekle-Smith 
followed the original plan to couple them and complete the synthesis of spongistatin 1 
analog. Using the exact EF fragment and a very similar ABCD fragment to the Smith 
route, she was able to closely follow literature precedent.48 ABCD* aldehyde 3.54 and EF 
Wittig salt 3.53 were successfully joined to form Wittig product 3.55 in 60% yield, which 
is comparable to the yield using natural ABCD (Scheme 3.19). This underwent selective 
silyl deprotection with TBAF3H2O to afford seco-acid 3.56 in 83% yield. This was a 
slightly improved yield, likely due to the higher reliability of using solid TBAF3H2O 
compared to the inconsistent commercially available TBAF in THF solution. Yamaguchi 
macrolactonization gave lactone 3.57 in 81% yield. Finally, global deprotection with 
hydrofluoric acid produced spongistatin 1 analog 3.58 in 83% yield. This was the first 




Scheme 3.19. Synthesis of spongistatin 1 analog 3.58 
 Upon completion of the synthesis, we were eager to confirm its activity through 













































































































































in collaboration with Dr. Dan Sackett at the National Institute of Health. The average 
GI50 value was 0.065 nM over two assays. Although natural spongistatin 1 was not tested 
with this cell line, this was within the range of .04 nM to 1.1 nM observed over 60 cell 
lines.20 This confirmed that spongistatin 1 analog has potent cytotoxic activity. The 
synthesis of spongistatin 1 analog was completed and efforts are underway to synthesize 
more analogs that could be developed into antibody drug conjugates. 
3.8. Summary, Conclusions and Outlook 
 Herein, we have described the synthesis of an EF Wittig salt suitable for coupling 
with any ABCD fragment. This was combined with the ABCD* fragment to successfully 
complete the synthesis of spongistatin 1 analog. The F-ring was prepared in large 
quantities in only eight steps. This validated the pseudosymmetric strategy to quickly 
build up stereochemical complexity.  
 The boron-mediated aldol reaction to connect the E and F-rings was high yielding 
and diastereoselective. This reaction introduced three more stereocenters to the molecule 
in a single step. The development of a one-pot asymmetric allylation led to a new 
generalized synthetic methodology with improved ease and scope over previous versions. 
This was successfully used to attach the side chain. This was a powerful proof of concept 
for the methodology, combining a heavily functionalized and sterically encumbered allyl 
halide with a very unstable aldehyde. This also represented the most efficient way to 
introduce the chlorodiene fragment. Additionally, a crystal structure of polyol 3.27 
confirmed 10 of the stereocenters on the EF fragment.  
 The sequence from methyl ketone 3.5 to EF fragment 3.53 was achieved in 10 
steps and 17% overall yield. This represents the most step-efficient route to the EF 
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fragment known. The longest linear sequence of the entire EF fragment synthesis was 18 
steps and 2% overall yield. This route was highly efficient and was used to generate a 
few hundred milligrams of the EF Wittig salt. Just four more steps furnished spongistatin 
1 analog. The biological testing results finally confirmed our structural hypothesis about 
the CD* spiroketal by proving that spongistatin 1 analog 3.58 has comparable biological 
activity to the natural spongistatin 1. With this knowledge, we have the capability to 

















3.9. Experimental Procedures 
General Information. All reactions were carried out under an atmosphere of argon in 
flame-dried glassware with magnetic stirring and dry solvents unless otherwise indicated. 
Degassed solvents were purified by passage through an activated alumina column. Et3N 
and i-Pr2NEt were distilled from CaH2. Synthesis of cis-crotyl trichlorosilane, trans-crotyl 
chloride, tridentate ligands (R,R)-3.10 and (R,R)-3.49, and ABCD* 3.54 were conducted 
as previously described,1,33 and all spectroscopic data were consistent with those reported 
for these compounds. Flash chromatography was performed with Silicycle SiliaFlash® 
P60 silica gel. pH 7 buffered silica gel was prepared by combining silica gel with 10% 
w/w dilute aqueous pH 7 phosphate buffer. Thin-layer chromatography (TLC) was 
carried out on glass backed silica gel TLC plates (250 mm) from Silicycle; visualization 
by UV light, KMnO4 and/or ceric ammonium molybdenate (CAM). 1H NMR spectra 
were recorded on a Bruker AVIII 300 (300 MHz), AVIII 400 (400 MHz), or AVIII 500 
(500 MHz) spectrometer and are reported in ppm, relative to residual protonated solvent 
peak (CDCl3, 7.26 ppm; C6D6, 7.16 ppm; CD3CN, 1.94 ppm; MeOH-d4, 3.31 ppm). Data 
are reported as follows: (bs= broad singlet, s = singlet, d = doublet, t = triplet, m = 
multiplet, dd = doublet of doublets, ddd = doublet of doublet of doublets, ddt = doublet of 
doublet of triplets, td = triplet of doublets, q = quartet, p = quintet; coupling constant(s) in 
Hz; integration). Proton decoupled 13C NMR spectra were recorded on a Bruker AVIII 
500 (126 MHz) spectrometer and are reported in relative to residual protonated solvent 
peak (CDCl3, 77.16 ppm; C6D6, 128.06 ppm; CD3CN, 1.32 ppm; MeOH-d4, 49.00 ppm). 
Infrared spectra were recorded on a Perkin-Elmer Spectrum Two (Diamond ATR) IR 
spectrometer.  Optical rotations were recorded on a Jasco DIP-1000 polarimeter. Mass 
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Spectroscopy data was obtained on a Waters XEVO G2-XS QToF mass spectrometer. X-
ray crystallography data was collected on an Agilent SuperNova diffractometer using 
mirror-monochromated Cu Kα radiation. 
 




 NaH (3.25 g, 81.4 mmol, 60% in mineral oil) was to THF (100 mL) and cooled to 
0 °C. A solution of 1,5-pentanediol 3.7 (49.5 g, 475 mmol) was dissolved in THF (100 
mL) and added over 30 min to the NaH slurry by addition funnel. After stirring for 30 
min at this temperature, a solution of BnBr (8.1 mL, 67.8 mmol) was dissolved in THF 
(100 mL) and added slowly by additional funnel to the reaction mixture that was stirred 
for 20 h at rt. H2O (10 mL) was added to quench the reaction. The entire reaction mixture 
was concentrated to remove THF. The crude residue was partitioned between H2O (500 
mL) and EtOAc (125 mL). The layers were separated and the aqueous layer was 
extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with H2O 
(6 x 100 mL), dried over Na2SO4 and concentrated to afford 3.8 contaminated with 
mineral oil. Spectroscopic data was consistent with that previously reported for this 









 DMSO (8.7 mL, 122 mmol) was added dropwise to a -78 °C solution of oxalyl 
chloride (8.7 mL, 102 mmol) in CH2CL2 (55 mL). The mixture was stirred for 10 min, 
then a solution of alcohol 3.8 dissolved in CH2Cl2 (110 mL) was added dropwise by 
additional funnel. The mixture was stirred at -78 °C for 30 min before Et3N (56 mL, 407 
mmol) was added dropwise. The reaction mixture was allowed to warm to rt and stirred 
another 30 min. Cold H2O (50 mL) was added and the layers were separated. The 
aqueous layer was extracted with CH2Cl2 (3 x 200 mL). The combined organic layers 
were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated. 
Purification by flash column chromatography (10% à 15% EtOAc/Hexanes) on silica 
gel gave aldehyde 3.9 as a yellow oil (11.5 g, 59.8 mmol, 87% yield over two steps). 




 (R,R)-3.10 (25.24 g, 86.90 mmol) was dissolved in CH2Cl2 (278 mL) and cooled 
to 0 ºC. DBU (39.00 mL, 260.7 mmol) was added, followed by dropwise addition of cis-
crotyl trichlorosilane 3.11b (14.6 mL, 95.60 mmol). The reaction was warmed to rt and 

















    0 °C to rt











added dropwise and the reaction was stirred for 3 h at this temperature. The reaction was 
concentrated, resuspended in Et2O (40 mL) and stirred for 1 h to precipitate salts. The 
reaction mixture was filtered, treated with TBAF (95 mL, 1M in THF) and stirred for 2 h. 
1M HCl (aq.)  (400 mL) was added and the mixture was extracted with Et2O (3 x 400 mL). 
The combined organic layers were washed with H2O (2 x 100 mL) and NaHCO3 (sat. aq) 
(100 mL). The organic layers was dried over Na2SO4, filtered, and concentrated to afford 
crude product. The aqueous layers were combined and treated with 1M NaOH (aq) (400 
mL) and extracted with CH2Cl2 (3 x 400 mL). These organic layers were combined, 
washed with H2O (100 mL) and brine (100 mL), dried over Na2SO4, filtered and 
concentrated to give recovered ligand. The crude product was purified by flash column 
chromatography (0% à 30% EtOAc/Hexanes) on silica gel to give alcohol 3.12 as a 
clear oil (16.2 g, 65.3 mmol, 79% yield, 97% ee). [α]D25 +17.7º (c 1.00, CH2Cl2). IR 
(ATR) 3420, 2934, 2859, 1738, 1638, 1453, 1363, 1098 cm-1.  1H NMR (500 MHz, 
CDCl3) δ 7.38 – 7.26 (m, 5H), 5.92 – 5.65 (m, 1H), 5.09 (d, J = 5.1 Hz, 1H), 5.06 (s, 1H), 
4.50 (s, 2H), 3.53 – 3.44 (m, 3H), 2.27 (q, J = 6.6 Hz, 1H), 1.72 – 1.35 (m, 6H), 1.02 (d, J 
= 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 141.13, 138.69, 128.47, 127.77, 127.63, 
115.40, 74.70, 73.03, 70.43, 43.56, 33.84, 29.83, 22.93, 14.18. HRMS (ESI+) calcd for 














 Alcohol (16.16 g, 65.06 mmol) was dissolved in CH2Cl2 (325 mL) and cooled to 
0 ºC. DMAP (794 mg, 6.50 mmol) and Et3N (13.6 mL, 97.5 mmol) were added, and then 
TES-Cl (13.1 mL, 78.1 mmol) was added dropwise. The reaction was warmed to rt, 
stirred for 3 h, quenched with MeOH (2.62 mL, 65 mmol) and concentrated. The crude 
mixture was suspended in hexane and stirred for 20 min. The mixture was filtered and 
concentrated. Purification by flash column chromatography (0 à 5% EtOAc/Hexanes) 
on silica gel afforded TES ether 3.13 as a colorless oil (23.6 g, 64.35 mmol, 99%). [α]D23 
+15.8º (c 1.00, CH2Cl2). IR (ATR) 2951, 2910, 2874, 1639, 1454, 1413, 1360, 1237, 
1100, 1006 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.27 (m, 5H), 5.93 – 5.76 (m, 
1H), 5.00 (d, J = 6.9 Hz, 1H), 4.98 (s, 1H), 4.50 (s, 2H), 3.55 (q, J = 7.5 Hz, 1H), 3.46 (td, 
J = 6.6, 1.0 Hz, 2H), 2.41 – 2.16 (m, 1H), 1.67 – 1.24 (m, 6H), 0.96 (t, J = 7.8 Hz, 9H), 
0.60 (q, J = 7.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 141.55, 138.84, 128.47, 127.73, 
127.59, 114.06, 76.16, 73.01, 70.58, 43.19, 33.87, 30.15, 22.24, 15.17, 7.17, 5.36. HRMS 




 To a solution of alkene (23.6 g, 64.35 mmol) in THF (90 mL), acetone (90 mL) 
and pH 7 buffer (90 mL) was added OsO4 (3.05 ml, 1.3 mmol, 4% in water) dropwise, 
followed by NMO (9.96 g, 85.00 mmol). The mixture was rapidly stirred for 24 h, then 
Na2SO3 (16.39 g, 130 mmol) in water (400 mL) was added and stirred for 1 h. The 















combined organic layers were dried over Na2SO4, filtered, and concentrated to give crude 
diol 3.14 that was used directly in the next step. 
 
 
 Crude diol 3.14 was dissolved in THF (900 mL) and pH 7 buffer (230 mL), then 
NaIO4 (27.8 g, 130 mmol) was added. After stirring for 20 h, the reaction was diluted 
with brine (1 L) and extracted with EtOAc (3 x 500 mL). The combined organic layers 
were dried over Na2SO4, filtered, and concentrated. Purification by flash column 
chromatography (0 à 5% EtOAc/Hexanes) on pH 7 buffered silica gel afforded aldehyde 
3.6 as a colorless oil (17.3 g, 47.45 mmol, 73% yield over two steps). [α]D24 +35.93º (c 
1.00, CH2Cl2). IR (ATR) 2938, 2874, 1724, 1454, 1360, 1238, 1101, 1030 cm-1. 1H 
NMR (500 MHz, C6D6) δ 9.62 (s, 1H), 7.32 (d, J = 7.0 Hz, 2H), 7.20 (t, J = 7.6 Hz, 2H), 
7.11 (t, J = 7.3 Hz, 1H), 4.34 (s, 2H), 4.01 – 3.94 (m, 1H), 3.29 (t, J = 6.2 Hz, 2H), 2.10 – 
2.01 (m, 1H), 1.55 – 1.17 (m, 6H), 1.03 – 0.89 (m, 12H), 0.55 (q, J = 8.0 Hz, 6H). 13C 
NMR (126 MHz, C6D6) δ 203.32, 139.42, 128.59, 127.78, 127.70, 73.11, 72.13, 70.18, 
51.39, 35.03, 30.22, 22.95, 7.63, 7.18, 5.52. HRMS (ESI+) calcd for [C21H36O3SiNH4+] 
requires m/z 382.2777, found 382.2781. 
 


















 Methyl ketone 3.15 (3.88 g, 6.97 mmol) was charged with Et2O (30 mL) and 
cooled to –78 ºC. Cy2BCl (3.1 mL, 13.9 mmol) was added, followed by Et3N (2.9 mL, 
20.9 mmol).  The reaction was warmed to 0 ºC and stirred for 3 h to give an off-white 
slurry.  The mixture was re-cooled to –78 ºC and a solution of aldehyde 3.6 (7.64 g, 20.9 
mmol) in Et2O (5 mL) was added.  The reaction was stirred 4 h at –78ºC, 14 h at –60 ºC, 
and then 1 h at 0 ºC.  The slurry was quenched by addition of NH4Cl (sat. aq.)  (100 mL), the 
layers separated, and the aqueous phase extracted with EtOAc (3 x 100 mL).  The 
combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to 
~50 mL. pH 7 buffered silica gel was added and the yellow solution was stirred at rt for 
30 min, then filtered with EtOAc washings (3 x 100 mL) of the filter cake. The filtrate 
was concentrated to afford the crude product as a yellow oil.  Purification by flash 
column chromatography (5% à 20% EtOAc/Hexanes) on pH 7 buffered silica gel gave 
3.16 as a mix of diastereomers as a pale yellow oil (5.53 g, 6.0 mmol, 86% yield, 2.5:1 
syn:anti). 1H NMR (500 MHz, C6D6) δ 7.37 – 7.02 (m, 20H), 5.45 (dtd, J = 9.2, 6.4, 3.0 
Hz, 2H), 4.87 (t, J = 11.3 Hz, 1H), 4.79 – 4.69 (m, 3H), 4.50 (t, J = 11.4 Hz, 1H), 4.43 
(dd, J = 11.4, 3.6 Hz, 1H), 4.36 (s, 3H), 4.32 (d, J = 5.7 Hz, 1H), 4.22 (dd, J = 11.4, 4.7 
Hz, 1H), 4.01 (q, J = 2.4 Hz, 1H), 3.92 – 3.86 (m, 1H), 3.45 (dd, J = 10.3, 2.5 Hz, 1H), 
3.41 – 3.33 (m, 4H), 3.23 – 3.17 (m, 2H), 3.10 – 3.00 (m, 2H), 2.90 – 2.80 (m, 1H), 2.39 
































1.24 (m, 17H), 1.23 – 1.04 (m, 7H), 1.01 (d, J = 7.9 Hz, 12H), 0.85 (d, J = 6.9 Hz, 1H), 
0.78 (d, J = 6.5 Hz, 1H), 0.76 – 0.69 (m, 4H), 0.64 (q, J = 8.0 Hz, 6H). This mixture was 
used directly in the next step.   
 
 
 Alcohol 3.16 (5.53 g, 6.0 mmol, 2.5:1 mix) was charged with dry MeOH (120 
mL).  Trimethylorthoformate (11.8 mL, 108 mmol) and PPTS (271 mg, 1.08 mmol) were 
added sequentially and the resulting mixture was stirred 2 h.  The reaction was slowly 
quenched by addition of NaHCO3 (sat. aq.) (150 mL) and the mixture extracted with EtOAc 
(3 x 125 mL).  The combined organic layers were washed with brine (100 mL), dried 
over Na2SO4, filtered, and concentrated. Purification by flash column chromatography 
(10 à 25% EtOAc/Hexanes with 1% Et3N) on silica gel afforded pure syn-methyl ketal 
3.17 as a clear oil (3.20 g, 3.89 mmol, 56% yield of syn diastereomer over two steps).   
 
 
 A solution of TBS-OTf (0.29 mL, 1.26 mmol) and 2,6-Lutidine (1.47 mL, 12.6 
mmol) in THF (4 mL) was cooled to –78ºC and prestirred 10 min.  The mixture was then 
added dropwise to a solution of alcohol 3.17 (515 mg, 0.63 mmol) in THF (30 mL) at –

















































and diluted with EtOAc (20 mL).  The layers were separated and the aqueous layer was 
extracted with EtOAc (3 x 15 mL).  The organic layers were combined, washed with 
brine (100 mL), dried over Na2SO4, filtered, and concentrated. Purification by flash 
column chromatography (2% à10% EtOAc/Hexanes with 1% Et3N) on silica gel 
afforded TBS ether 3.18 (476 mg, 0.51 mmol, 81% yield). 1H NMR (400 MHz, CDCl3) δ 
7.62 – 6.81 (m, 20H), 5.31 (d, J = 7.8 Hz, 2H), 4.91 (d, J = 11.7 Hz, 1H), 4.86 – 4.73 (m, 
2H), 4.65 – 4.45 (m, 4H), 4.18 – 4.09 (m, 1H), 3.98 – 3.86 (m, 1H), 3.80 (s, 1H), 3.58 – 
3.46 (m, 3H), 3.24 – 3.02 (m, 7H), 2.34 – 2.25 (m, 2H), 2.07 – 1.18 (m, 19H), 0.88 (s, 
9H), 0.44 (d, J = 6.4 Hz, 3H), 0.00 (d, J = 9.1 Hz, 6H). 
 




 To a –78 ºC solution of TBS ether 3.18 (600 mg, 0.641 mmol) in THF (30 mL) 
was added LiDBB [(~0.48 M in THF) freshly prepared by sonication of Li granules (117 
mg, 16.9 mmol) and 4,4-di-t-butyl-biphenyl (4.10 g, 15.4 mmol) in THF (35 mL) at 0 ºC 
for 3.5 h] slowly via syringe. The reaction was stirred at –78 ºC for 1 h, then at –40 ºC for 
2 h and finally –20 ºC for 1 h. The reaction was then quenched by the addition of NH4Cl 
(sat. aq.) (50 mL), diluted with ethyl acetate (50 ml) and warmed to room temperature. The 
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combined organic extracts were dried over Na2SO4, filtered, and concentrated. 
Purification by flash column chromatography (1% to 10% MeOH/CH2Cl2) on silica gel 
afforded tetraol 3.19 (304 mg, 0.53 mmol, 82% yield) as an amorphous white solid. 






 To a 0 ºC solution of tetraol 3.19 (840 mg, 1.46 mmol) in dry DMF (81 ml) was 
added imidazole (2.98 g, 43.8 mmol). TES-Cl (4.9 mL, 28.9 mmol) was added dropwise 
over 15 min. The reaction mixture was stirred overnight at rt and diluted with Et2O (75 
mL). This mixture was slowly added to a stirred 0 ºC solution of NaHCO3(sat. aq) (100 
mL). The layers were separated and the aqueous layer was extracted with Et2O (3 x 50 
mL). The combined organic layers were washed with H2O (2 x 50 mL) and brine (50 
mL). The combined aqueous layers were extracted with Et2O (75 mL), which was added 
to the combined organic layers were all dried over Na2SO4, filtered and concentrated. 
Purification by flash column chromatography (0% à 2% EtOAc/Hexanes with 1% Et3N) 
on silica gel afforded TES ether 3.20 as a clear oil (1.40 g, 1.36 mmol, 93% yield). 




























 A solution of 3.20 (265 mg, 0.242 mmol) in CH2Cl2 (18 mL) was cooled to -78 ºC 
while flushing with O2 over 5 min. The reaction solution was flushed with O3 until the 
solution turned blue (~5 min.). The resulting solution was flushed with O2 for 5 min to 
give a colorless solution. Et3N (1.68 mL, 12.1 mmol) and Me2S (0.17 mL, 2.42 mmol) 
were added. The solution was allowed to warm to rt overnight. Eschenmoser’s salt (224 
mg, 1.21 mmol) was added and the reaction mixture was stirred for 16 h. The reaction 
was quenched by the addition of NaHCO3(sat. aq) (15 mL) and the layers were separated. 
The aqueous layer was extracted with CH2Cl2 (2 x 10 mL). The combined organic layers 
were washed with H2O (10 mL) and brine (10 mL), dried over Na2SO4, filtered and 
concentrated. Purification by flash column chromatography (0% à 4% EtOAc/Hexanes) 
on pH 7 buffered silica gel afforded enal 3.21 as a clear oil (134 mg, 0.132 mmol, 54% 





 To a -78 ºC solution of enal 3.21 (150 mg, 0.147 mmol) in CH2Cl2 (18 mL) was 












1. O3, CH2Cl2, -78 °C
2. Me2S, Et3N








































quenched with Rochelle’s Salt (sat. aq) (20 mL) and stirred vigorously at rt for 2 h. The 
layers were separated and the aqeous layer was extracted with CH2Cl2 (2 x 15 mL). The 
combined organic layers were washed with NaHCO3(sat. aq) (25 mL), dried over Na2SO4, 
filtered and concentrated. Purification by flash column chromatography (0% à 7% 
EtOAc/Hexanes with 1% Et3N) on silica gel afforded allyl alcohol 3.22 as a clear oil (101 
mg, 0.10 mmol, 67% yield). Spectroscopic data was consistent with that previously 
reported for this compound. 
 
 
 To a 0 ºC solution of allyl alcohol 3.23 (77 mg, 0.075 mmol) in CH2Cl2 (3 mL) 
was added Et3N (0.11 mL, 0.75 mmol), PPh3 (59 mg, 0.225 mmol), and CBr4 (75 mg, 
0.225 mmol) sequentially.  The reaction mixture was stirred at rt for 1 h, and then 
quenched by addition of NaHCO3(sat. aq) (5 mL).  The layers were separated and the 
aqueous layer was extracted with Et2O (2 x 5 mL).  The combined organic layers were 
dried over Na2SO4, filtered, and concentrated.  Purification by flash column 
chromatography (0% à 3% EtOAc/Hexanes with 1% Et3N) on silica gel afforded allyl 
bromide 3.23 as a pale oil (73 mg, 0.067 mmol, 90% yield). Spectroscopic data was 
consistent with that previously reported for this compound. 
 
































 Methyl ketone 3.5 (5.23 g, 8.24 mmol) was charged with Et2O (33 mL) and 
cooled to –78 ºC.  Cy2BCl (3.6 mL, 16.48 mmol) was added, followed by Et3N (3.42 mL, 
24.72 mmol).  The reaction was warmed to 0 ºC and stirred for 3 h to give an off-white 
slurry.  The mixture was re-cooled to –78 ºC and a solution of aldehyde 3.6 (9.01 g, 24.72 
mmol) in Et2O (9 mL) was added.  The reaction was stirred 4 h at –78ºC, 14 h at –60 ºC, 
and then 1 h at 0 ºC.  The slurry was quenched by addition of NH4Cl (sat. aq.)  (150 mL), the 
layers separated, and the aqueous layer extracted with EtOAc (3 x 100 mL).  The 
combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to 
~100 mL.  pH 7 buffered silica gel was added and the yellow solution was stirred at room 
temperature for 30 min, then filtered with EtOAc washings (3 x 100 mL) of the filter 
cake.  The filtrate was concentrated under reduced pressure to afford the crude product as 
a yellow oil.  Purification by flash column chromatography (5% à 20% EtOAc/Hexanes) 
on pH 7 buffered silica gel gave 3.24 as a pale yellow oil (6.89 g, 6.88 mmol, 84% yield, 
11:1 syn:anti).  Major Diastereomer (syn): [α]D20 –28.5º (c 2.00, CH2Cl2).  IR (ATR) 
3511, 3029, 2873, 1711, 1494, 1453, 1360, 1091, 1070 cm–1. 1H NMR (500 MHz, C6D6) 
δ 7.37 (d, J = 7.5 Hz, 2H), 7.28 – 7.35 (m, 5H), 7.14 – 7.24 (m, 8H), 7.00 – 7.13 (m, 
10H), 5.29 (s, 1H), 5.05 (s, 1H), 4.85 (d, J = 11.0 Hz, 1H), 4.75 – 4.79 (m, 1H), 4.76 (d, J 































ΔνAB = 18.1 Hz, JAB = 11.9 Hz), 4.43 (d, J = 11.5 Hz, 1H), 4.36 (s, 2H), 4.22 (d, J = 11.5 
Hz, 1H), 4.01 (ABq, 2H, ΔνAB = 37.3 Hz, JAB = 13.2 Hz), 4.00 – 4.03 (m, 1H), 3.84 (d, J 
= 2.5 Hz, 1H), 3.45 (dd, J = 17.2, 9.8 Hz, 1H), 3.43 (td, J = 9.4, 2.5 Hz, 1H), 3.37 (dd, J 
= 10.2, 2.5 Hz, 1H), 3.34 (t, J = 6.4 Hz, 2H), 3.28 (d, J = 1.4 Hz, 1H), 3.21 (t, J = 9.3 Hz, 
1H), 3.01 (dd, J = 10.4, 8.9 Hz, 1H), 2.75 (d, J = 14.5 Hz, 1H), 2.69 (dd, J = 17.3, 2.3 Hz, 
1H), 2.35 (qq, J = 10.1, 6.4 Hz, 1H), 2.20 (dd, J = 15.0, 9.7 Hz, 1H), 1.54 – 1.75 (m, 5H), 
1.42 (p, J = 7.7 Hz, 2H), 1.12 (d, J = 7.0 Hz, 3H), 1.01 (t, J = 7.9 Hz, 9H), 0.73 (t, J = 7.9 
Hz, 3H), 0.63 (q, J = 7.9 Hz, 6H).  13C NMR (126 MHz, C6D6) δ 213.8, 144.8, 140.0, 
140.0, 139.8, 139.7, 138.5, 129.3, 129.3, 129.2, 129.2, 129.1, 129.1, 128.9, 128.8 128.7, 
128.6, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 128.2, 128.2, 114.0, 87.2, 84.7, 84.2, 
83.4, 78.9, 78.0, 75.9, 75.4, 74.1, 73.9, 73.7, 72.8, 71.2, 70.9, 45.9, 42.0, 38.9, 36.8, 35.7, 
31.1, 23.2, 13.1, 8.1, 7.9, 6.4.  HRMS (ESI+) calcd for [C62H82O9SiNa+] requires m/z 





 Alcohol 3.24 (6.89 g, 6.90 mmol) was charged with dry MeOH (138 mL).  
Trimethylorthoformate (13.8 mL, 124 mmol) and PPTS (607 mg, 2.42 mmol) were added 
sequentially and the resulting mixture was stirred 2 h.  The reaction was slowly quenched 
by addition of NaHCO3 (sat. aq.) (175 mL) and the mixture extracted with EtOAc (3 x 125 



























Na2SO4, filtered, and concentrated.  Purification by flash column chromatography (10 à 
25% EtOAc/Hexanes with 1% Et3N) on silica gel afforded hemiketal 3.25 as a clear oil 
(4.47 g, 5.00 mmol, 70% yield).  [α]D20 +19.0º (c 2.0, CH2Cl2).  IR (ATR) 3527, 3029, 
2858, 1495, 1454, 1356, 1213, 1090, 1062, 1025 cm–1. 1H NMR (500 MHz, C6D6) δ 7.40 
(t, J = 7.0 Hz, 4H), 7.35 (d, J = 7.0 Hz, 2H), 7.31 (d, J = 7.4 Hz, 2H), 7.24 (d, J = 7.0 Hz, 
2H), 7.00 – 7.21 (m, 15 H), 5.39 (s, 1H), 5.17 (s, 1H), 4.99 (d, J = 11.2 Hz, 1H), 4.92 (d, 
J = 11.4 Hz, 1H), 4.74 (d, J = 11.4 Hz, 1H), 4.58 (d, J = 11.1 Hz, 1H), 4.55 (d, J = 11.6 
Hz, 1H), 4.47 (d, J = 11.7 Hz, 2H), 4.37 (d, J = 12.1 Hz, 1H), 4.36 (s, 2H), 4.22 (d, J = 
12.7 Hz, 1H), 4.12 – 4.16 (m, 1H), 4.10 (d, J = 12.7 Hz, 1H), 3.90 – 3.96 (m, 1H), 3.87 
(d, J = 9.0 Hz, 1H), 3.58 (td, J = 9.0, 2.6 Hz, 1H), 3.56 (s, 1H), 3.38 (t, J = 6.1 Hz, 2H), 
3.27 (t, J = 9.1 Hz, 1H), 3.14 (dd, J = 10.2, 1.3 Hz, 1H), 3.06 (dd, J = 10.5, 8.7 Hz, 1H), 
2.95 (s, 3H), 2.83 (d, J = 14.1 Hz, 1H), 2.49 (ABX, 2H, ΔνAB = 22.8 Hz,  JAB = 15.3 Hz, 
JBX = 3.3 Hz, JAX = 2.1 Hz), 2.32 (dd, J = 14.9, 9.4 Hz, 1H), 2.22 (ddt, J = 16.7, 10.4, 6.4 
Hz, 1H), 1.76 – 1.83 (m, 1H), 1.67 – 1.75 (m, 2H), 1.65 (p, J = 6.2 Hz, 2H), 1.40 – 1.50 
(m, 1H), 1.23 – 1.33 (m, 1H), 0.80 (d, J = 7.1 Hz, 3H), 0.71 (d, J = 6.5 Hz, 3H). 13C 
NMR (126 MHz, C6D6) δ 144.6, 140.2, 140.0, 140.0, 139.9, 139.7, 129.4, 129.2, 129.2, 
129.1, 129.1, 128.9, 128.8, 128.7, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 
128.2, 128.1, 115.1, 105.1, 87.7, 84.1, 80.9, 78.8, 77.6, 75.8, 75.5, 75.3, 74.1, 73.7, 72.6, 
71.3, 70.9, 68.6, 48.0, 39.4, 38.5, 37.0, 33.8, 31.1, 30.8, 24.0, 13.8, 11.5.  HRMS (ESI+) 





 A solution of TBS-OTf (2.51 mL, 10.94 mmol) and 2,6-lutidine (4.23 mL, 36.48 
mmol) in THF (24 mL) was cooled to –78ºC and prestirred 5 min.  The mixture was then 
added dropwise to a solution of hemiketal 3.25 (3.28 g, 3.65 mmol) in THF (180 mL) at –
78ºC.  The reaction was stirred 1 h, then quenched by addition of NaHCO3(sat. aq) (150 
mL) and diluted with EtOAc (150 mL).  The layers were separated and the aqueous layer 
was extracted with EtOAc (3 x 150 mL).  The organic layers were combined, washed 
with brine (100 mL), dried over Na2SO4, filtered, and concentrated. Purification by flash 
column chromatography (10% EtOAc/Hexanes) on pH 7 buffered silica gel afforded TBS 
ether 3.26 as a pale yellow oil (3.15 g, 3.19 mmol, 87% yield). [α]D21 +18.0º (c 2.00, 
CH2Cl2).  IR (ATR) 3029, 2931, 2853, 1494, 1454, 1360, 1250, 1209, 1095, 1070, 1025 
cm–1. 1H NMR (500 MHz, C6D6) δ 7.47 (d, J = 7.1 Hz, 2H), 7.35 (t, J = 7.0 Hz, 4H), 7.31 
(d, J = 7.0 Hz, 2H), 7.27 (d, J = 7.5 Hz, 2H), 7.02 – 7.22 (m, 15 H), 5.38 (s, 1H), 5.16 (s, 
1H), 5.07 (d, J = 11.3 Hz, 1H), 4.88 (d, J = 11.4 Hz, 1H), 4.80 (d, J = 11.5 Hz, 1H), 4.67 
(d, J = 11.2 Hz, 1H), 4.53 (d, J = 11.2 Hz, 2H), 4.44 (ABq, 2H, ΔνAB = 24.5 Hz, JAB = 
12.5 Hz), 4.36 (s, 2H), 4.31 – 4.36 (m, 1H), 4.19 (ABq, 2H, ΔνAB = 50.5 Hz, JAB = 13.2 
Hz), 3.86 (q, J = 3.1 Hz, 1H), 3.65 (s, 1H), 3.55 (td, J = 7.7, 2.6 Hz, 1H), 3.38 (t, J = 5.9 
Hz, 2H), 3.33 (t, J = 9.1 Hz, 1H), 3.28 (d, J = 10.4 Hz, 1H), 3.20 (s, 3H), 3.05 (dd, J = 
10.4, 8.7 Hz, 1H), 2.83 (d, J = 14.4 Hz, 1H), 2.51 (dd, J = 15.5, 3.9 Hz, 1H), 2.42 (dd, J = 



























1.79 (m, 4H), 1.49 – 1.60 (m, 2H), 1.33 – 1.44 (m, 1H), 1.09 (s, 9H), 0.89 (d, J = 7.1 Hz, 
3H), 0.76 (d, J = 6.5 Hz, 3H), 0.20 (s, 3H), 0.10 (s, 3H). 13C NMR (126 MHz, C6D6) δ 
144.7, 140.2, 140.2, 140.1, 140.1, 129.2, 129.1, 129.1, 129.1, 128.9, 128.8, 128.7, 128.6, 
128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.1, 128.1, 128.1, 114.7, 103.5, 87.9, 83.6, 
80.4, 78.9, 77.6, 75.8, 75.7, 75.1, 74.6, 73.6, 72.8, 71.7, 71.0, 67.9, 47.9, 39.7, 39.2, 36.9, 
33.8, 32.1, 31.1, 26.8, 24.0, 19.0, 13.9, 11.1, -3.6, -3.9. HRMS (ESI+) calcd for 




 To a –78 ºC solution of TBS Ether 3.26 (960 mg, 0.949 mmol) in THF (57 mL) 
was added LiDBB [(~0.48 M in THF) freshly prepared by sonication of Li granules (415 
mg, 29.61 mmol) and 4,4-di-tert-butyl-biphenyl (7.28 g, 27.33 mmol) in THF (57 mL) at 
0 ºC for 3.5 h] slowly via syringe. The reaction was stirred at –78 ºC for 2 h, then 
switched to a –30 ºC bath and stirred for a further 16 h. The reaction was then quenched 
by the addition of NH4Cl (sat. aq.) (150 mL), diluted with ethyl acetate (150 ml) and 
warmed to room temperature. The aqueous phase was extracted with ethyl acetate (75 ml) 
and methylene chloride (2 x 75 mL). The organic extracts were dried over Na2SO4, 
filtered, and concentrated. Purification by flash column chromatography (1% à 10% 
MeOH/CH2Cl2) on silica gel afforded polyol 3.27 as an amorphous white solid. (460 mg, 
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of a dichloromethane solution. [α]D25 +22.2º (c 1.00, MeOH).  IR (ATR) 3316, 2942, 
2831, 1448, 1401, 1402, 1113, 1023 cm-1. 1H NMR (500 MHz, MeOH-d4) δ 5.15 (d, J = 
1.9 Hz, 1H), 5.02 (s, 1H), 4.25 – 4.17 (m, 1H), 4.08 (s, 2H), 3.86 (d, J = 2.8 Hz, 1H), 3.75 
(s, 1H), 3.61 (t, J = 6.2 Hz, 2H), 3.41 – 3.34 (m, 4H), 3.32 (d, J = 10.3 Hz, 1H), 3.22 (s, 
3H), 3.12 (d, J = 17.1 Hz, 2H), 2.70 (d, J = 14.5 Hz, 1H), 2.29 (dd, J = 14.6, 8.4 Hz, 1H), 
2.10 (dd, J = 15.4, 3.9 Hz, 1H), 1.86 – 1.79 (m, 1H), 1.72 – 1.41 (m, 5H), 1.07 (d, J = 6.5 
Hz, 3H), 0.96 (s, 9H), 0.93 (d, J = 7.1 Hz, 3H), 0.13 (s, 3H), 0.09 (s, 3H). 13C NMR (126 
MHz, MeOH-d4) δ 147.31, 113.49, 102.32, 79.98, 79.73, 79.60, 76.01, 71.90, 71.15, 
67.99, 66.67, 62.85, 47.95, 47.76, 40.13, 39.48, 36.63, 33.79, 33.56, 31.43, 26.35, 23.58, 
18.88, 13.50, 10.37, 9.23, -4.24, -4.65. HRMS (ESI+) calcd for [C28H54O9SiNa+] 
requires m/z 585.3435, found 585.3443. 
 




 Polyol 3.27 (428 mg, 0.76 mmol) and 2,6-Lutidine (0.35 mL, 3.04 mmol) were 
suspended in CH2Cl2 (76 mL) and cooled to –78 ºC. TES-Cl (0.067 mL, 0.40 mmol) was 
added dropwise and the reaction was stirred for 2 h at this temperature. An additional 
portion of TES-Cl (0.067 mL, 0.40 mmol) was added and the reaction mixture was stirred 




























NaHCO3(sat. aq) (50 mL) and the layers separated. The aqueous layer was extracted with 
CH2Cl2 (2 x 50 mL) and EtOAc (50 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated. Purification by flash column chromatography (80% à 
100% EtOAc/Hexanes) on pH 7 buffered silica silica gel afforded tetraol 3.29 as a clear 
oil (214 mg, 0.316 mmol, 42% yield). 1H NMR (300 MHz, C6D6) δ 5.26 (s, 1H), 5.17 (s, 
1H), 4.40 – 4.10 (m, 4H), 3.90 (d, J = 21.8 Hz, 2H), 3.62 (t, J = 5.8 Hz, 2H), 3.53 – 3.37 
(m, 3H), 3.20 (s, 3H), 2.87 – 2.57 (m, 1H), 2.32 (q, J = 6.4 Hz, 3H), 2.20 – 2.06 (m, 1H), 
1.87 (d, J = 15.1 Hz, 1H), 1.80 – 1.22 (m, 5H), 1.13 – 1.00 (m, 18H), 0.94 (d, J = 7.0 Hz, 




 To a 0 ºC of polyol 3.27 (370 mg, 0.658 mmol) in DMF (36 mL) was added 
imidazole (1.57 g, 23.04 mmol) and TES-Cl (2.76 ml, 16.45 mmol). The solution was 
stirred overnight at 35 ºC. The reaction mixture was diluted with Et2O (100 mL), cooled 
to 0 ºC and added to a stirring solution of NaHCO3(sat. aq) (150 mL). The layers were 
separated and the aqueous layer extracted with Et2O (3 x 50 mL). The organic layers 
were washed with water (2 x 50 mL) and brine (50 mL). The combined aqueous layers 
were extracted with Et2O (75 mL). The combined organic extracts were dried over 
Na2SO4, filtered, and concentrated in vacuo overnight. To the crude product was added 






























The reaction mixture was diluted with CH2Cl2 (200 mL) and quenched with NaHCO3(sat. 
aq) (300 mL). The layers were separated, the aqueous layer was extracted with CH2Cl2 (3 
x 75 mL) and the combined organic layers dried over Na2SO4, filtered, and concentrated. 
Purification by flash column chromatography (5% EtOAc/Hexanes with 1% Et3N) on 
silica gel afforded diol 3.30 as a colorless oil (440 mg, 0.487 mmol, 74% yield. [α]D22 
+35.1º (c 1.00, CH2Cl2). IR (ATR) 3421, 2952, 2876, 1459, 1414, 1378, 1237, 1079, 
1006 cm-1. 1H NMR (500 MHz, C6D6) δ 5.11 (d, J = 1.8 Hz, 1H), 5.02 (s, 1H), 4.32 – 
4.21 (m, 3H), 3.97 (d, J = 2.9 Hz, 1H), 3.88 (s, 1H), 3.64 (t, J = 6.5 Hz, 1H), 3.60 – 3.49 
(m, 3H), 3.44 – 3.38 (m, 3H), 3.13 (s, 3H), 2.74 – 2.65 (m, 2H), 2.34 (dd, J = 15.1, 3.7 
Hz, 1H), 2.02 – 1.94 (m, 1H), 1.74 – 1.54 (m, 3H), 1.41 – 1.28 (m, 1H), 1.18 (t, J = 8.0 
Hz, 9H), 1.13 – 1.03 (m, 27H), 1.00 (d, J = 7.2 Hz, 3H), 0.92 – 0.66 (m, 18H), 0.22 (s, 
3H), 0.14 (s, 3H). 13C NMR (126 MHz, C6D6) δ 148.71, 128.59, 111.94, 101.51, 82.08, 
80.42, 77.68, 76.92, 71.59, 71.37, 67.69, 67.06, 62.64, 46.99, 40.27, 38.94, 37.60, 33.43, 
33.10, 30.21, 26.18, 22.97, 18.41, 16.15, 10.75, 7.55, 7.45, 7.37, 6.19, 6.11, -4.10, -4.64. 




 Diol 3.30 (207 mg, 0.229 mmol) and 2,6-Lutidine (0.1 mL, 0.916 mmol) were 
dissolved in CH2Cl2 (23 mL) and cooled to –78 ºC. TES-Cl (0.021 mL, 0.126 mmol) was 




























portion of TES-Cl (0.021 mL, 0.126 mmol) was added and the reaction mixture was 
stirred for 2 h at this temperature. The reaction was quenched by the addition of 
NaHCO3(sat. aq) (25 mL) and the layers separated. The aqueous layer was extracted with 
CH2Cl2 (3 x 20 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated. Purification by flash column chromatography (3% à 20% 
EtOAc/Hexanes) on pH 7 buffered silica silica gel afforded allyl alcohol 3.22 as a clear 
oil (227 mg, 0.222 mmol, 97% yield). 




 To a 0 ºC solution of 3-methyl-3-buten-1-ol 3.39 (10 mL, 99.2 mmol) in THF 
(107 mL) was added slowly a solution of TES-Cl (17.5 mL, 104 mmol) in THF (17 mL). 
The reaction mixture was allowed to warm to rt over 1.5 h. NH4Cl (sat. aq.) (150 mL) and 
Et2O (200 mL) were added to quench the reaction and the layers were separated. The 
aqueous layer was extracted with Et2O (2 x 100 mL). The combined organic layers were 
dried over MgSO4, filtered and concentrated to afford pure TES ether 3.40 (18.8 g, 93.6 












 To a 0 ºC solution of TES ether 3.40 (5.0 g, 25.0 mmol) in CH2Cl2 (150 mL) was 
added NaHCO3 (5.58 g, 66.4 mmol) and mCPBA (7.81 g, 33.2 mmol, 73% purity). The 
reaction mixture was stirred at 0 ºC for 3 h and at rt for 30 min. H2O (200 mL) and Et2O 
(200 mL) were added and the layers were separated. The aqueous layer was extracted 
with Et2O (3 x 100 mL). The combined organic layers were washed with brine (100 mL), 
dried over Na2SO4, filtered and concentrated. Purification by flash column 
chromatography (0% à 6% EtOAc/Hexanes) on silica gel afforded epoxide 3.41 as a 
clear oil (4.07 g, 18.8 mmol, 75% yield). Spectroscopic data was consistent with that 
previously reported for this compound. 
 
 
 To a 0 ºC solution of 2,2,6,6-Tetramethylpiperdine (20.4 mL, 120 mmol) in 
benzene (310 mL) was added n-BuLi (54 mL, 2.22M) dropwise.  The resulting mixture 
was stirred 30 min, and then cooled to –78 ºC.  Diethylaluminum chloride (25% in 
toluene, 62.3 mL, 114.6 mmol) was added slowly, and then the mixture was warmed to 0 
ºC for 45 min.  A solution of epoxide 3.41 (11.3 g, 52.1 mmol) in benzene (10 mL) was 

























salt (sat. aq) (200 mL) was added and the mixture was stirred vigorously for 1 hr.  The 
layers were separated, and the aqueous layer was extracted with Et2O (3 x 75 mL).  The 
combined organic layers were dried over Na2SO4, filtered, and concentrated. The crude 
mixture was subjected to high-vaccum at 40 ºC to remove 2,2,6,6-Tetramethylpiperdine.  




 To a 0 ºC solution of allyl alcohol 3.42 in CH2Cl2 (90 mL) was added Et3N (6.4 
mL, 46.2 mmol), PPh3 (4.85 g, 18.5 mmol), and CBr4 (6.13 g, 18.5 mmol) sequentially.  
The reaction mixture was stirred at rt for 1 h, and then quenched by addition of 
NaHCO3(sat. aq) (90 mL).  The layers were separated and the aqueous layer was extracted 
with Et2O (2 x 50 mL).  The combined organic layers were dried over Na2SO4, filtered, 
and concentrated.  Purification by flash column chromatography (0% à 2% 
EtOAc/Hexanes) on silica gel afforded allyl bromide 3.43 as a clear oil (4.37 g, 15.6 
mmol, 90% yield).  IR (ATR) 2953, 2875, 1640, 1458, 1413, 1381, 1238, 1208 cm–1. 1H 
NMR (500 MHz, CDCl3) δ 5.22 (d, J = 1.2 Hz, 1H), 5.01 (q, J = 1.2 Hz, 1H), 4.01 (d, J = 
0.8 Hz, 2H), 3.77 (t, J = 6.7 Hz, 2H), 2.44 (td, J = 6.7, 1.2 Hz, 2H), 0.96 (t, J = 8.0 Hz, 
9H), 0.60 (q, J = 7.9 Hz, 6H).  13C NMR (126 MHz, CDCl3) δ 143.4, 116.8, 61.9, 37.4, 












3.9.7. Preparation of aldehyde 3.2 
 
 
 To a -78 ºC solution of oxalyl chloride (5.6 mL, 65.2 mmol) in THF (106 mL) 
was added a mixture of DMSO (5.7 mL, 80.2 mmol) and THF (5 mL) dropwise. The 
reaction was allowed to warm to -40 ºC over 30 min. Upon re-cooling to -78 ºC, 2-chlor-
2-propen-1-ol 3.44 (4.62 g, 50.2 mmol) was added and the reaction was allowed to warm 
to -40 ºC over 1 h. Et3N (36.3 mL, 261 mmol) was added and reaction was allowed to 
warm to rt over 1 h. Et2O (50 mL) was added to precipitate salts. The mixture was air-
free filtered into another flask. A second portion of Et2O (50 mL) was used to rinse the 
reaction flask and filter cake. This clear solution of 2-chloroacrolein was kept at -78 ºC 
under argon. 
 In a separate flask, triethylphosphonoacetate (6.6 mL, 33.1 mmol) was charged 
with THF (155 mL) and cooled to -78 ºC. NaHMDS (36.6 mL, 1M in THF) was added 
dropwise, followed by addition of catechol (500 mg). The resultant blue solution was 
stirred for 15 min. The cold 2-chloroacrolein solution was added and the reaction mixture 
was stirred at -78 ºC for 1.5 h, then overnight at -20 ºC. The reaction was quenched by 
the addition of Et2O (200 mL) and H2O (175 mL). The layers were separated and the 
aqueous layer was extracted with EtOAc (3 x 100 mL). The combined organic layers 
were dried over Na2SO4, filtered and concentrated. Purification by flash column 

















(2.95 g, 18.4 mmol, 55% yield). Spectroscopic data was consistent with that previously 




 To a -78 ºC solution of ester 3.45 (895 mg, 5.58 mmol) in CH2Cl2 (65 mL) was 
added DIBAL (22.3 mL, 1M in CH2Cl2). The reaction was stirred at this temperature for 
1.5 h before quenching with Rochelle’s salt (sat. aq) (100 mL) and vigorously stirring for 4 
h. The layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 50 
mL). The combined organic layers were dried over MgSO4, filtered and concentrated. . 
Purification by flash column chromatography (CH2Cl2) on silica gel afforded alcohol 
3.46 as an unstable oil (665 mg, 4.13 mmol, 74% yield). This was dissolved in CH2Cl2 to 
form a 0.4M solution that was stable in the freezer. Spectroscopic data was consistent 




 To a -78 ºC solution of oxalyl chloride (0.74 mL, 8.60 mmol) in CH2Cl2 (4 mL) 
was added a solution of DMSO (1.27 mL, 17.2 mmol) in CH2Cl2 (17 mL). The reaction 



















CH2Cl2) was added and the resultant mixture was allowed to stir at this temperature for 
15 min. Et3N (3.6 mL, 25.8 mmol) was added and the reaction mixture was stirred at -78 
ºC for 1 h. The reaction was quenched by the addition of H2O (20 mL). The layers were 
separated and aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined 
organic layers were washed with H2O (3 x 10 mL), dried over Na2SO4, filtered and 
carefully concentrated to afford aldehyde 3.2 (446 mg, 3.83 mmol, 89% yield) that was 
used immediately in the subsequent reaction without further purification. Spectroscopic 
data was consistent with that previously reported for this compound. 
 
 
 In an argon-atmosphere glovebox, copper (I) chloride (1 mg, 0.0115 mmol) was 
placed in a 2-dram vial with a stir bar.  The vial was capped with a septum and 
transferred out of the glove box.  The vessel was then charged with CH2Cl2 (0.8 mL) and 
Et3N (16.3 mg, 0.161 mmol), then cooled to 0 ºC.  In a separate vial under Ar 
atmosphere, allyl bromide 3.43 (64 mg, 0.23 mmol) was charged with CH2Cl2 (0.8 mL), 
Et3N (16.3 mg, 0.161 mmol), and HSiCl3 (37.4 mg, 0.276 mmol) sequentially (base must 
be added first to prevent acid-mediated degradation).  The solution was mixed, then 
transferred dropwise via syringe to the 0 ºC CuCl/Et3N solution.  The allyl bromide vial 
was then rinsed with CH2Cl2 (0.2 mL), this solution was added to the reaction flask, and 
the resulting mixture was stirred for 2 h at 0 ºC.  A solution of the (R,R)-3.10 (66.8 mg, 














added dropwise via syringe to the reaction mixture.  The cooling bath was removed and 
the mixture was stirred 1 h at rt.  The silane solution was then re-cooled to –40 ºC and 
aldehyde 3.2 (53.4 mg, 0.46 mmol) was added. The reaction was stirred at 0 ºC for 1 h. 
The reaction mixture was re-cooled to –40 ºC and treated with TBAF3H2O (87 mg, 
0.276 mmol) and stirred 1 h at –40 ºC.  The mixture was then passed through a silica plug 
with EtOAc and concentrated to give the crude product. Purification by flash column 
chromatography (10% EtOAc/Hexanes) on silica gel afforded alcohol 3.47 as a clear oil 
(46 mg, 0.145 mmol, 63% yield). The ee of the compound was determined to be 90% 
based on 19F analysis of the corresponding Moscher ester. [α]D23 –1.2º (c 1.00, CH2Cl2).  
IR (ATR) 3346, 2954, 2913, 2875, 1645, 1590, 1456, 1413, 1381, 1238 cm–1. 1H NMR 
(500 MHz, CDCl3) δ 6.41 (dd, J = 14.9, 1.5 Hz, 1H), 6.16 (dd, J = 14.9, 5.1 Hz, 1H), 5.35 
(s, 2H), 4.98 (d, J = 4.6 Hz, 2H), 4.42 (dq, J = 9.0, 4.4 Hz, 1H), 3.77 (t, J = 6.5 Hz, 2H), 
2.64 (d, J = 3.2 Hz, 1H), 2.41 (dd, J = 14.1, 3.7 Hz, 1H), 2.32 (t, J = 6.4 Hz, 2H), 2.23 
(dd, J = 14.1, 9.6 Hz, 1H), 0.96 (t, J = 7.9 Hz, 9H), 0.61 (q, J = 8.0 Hz, 6H). 13C NMR 
(126 MHz, CDCl3) δ 143.6, 138.5, 137.1, 126.7, 115.6, 115.3, 69.4, 62.4, 45.3, 38.9, 6.9, 





Figure 3.2. 19F NMR Moscher ester analysis of 3.47 
 




 In an argon-atmosphere glovebox, copper (I) bromide (0.9 mg, 0.0063 mmol) was 
placed in a flame-dried vial with a stir bar.  The vial was capped with a septum and 
transferred out of the glove box.  The vessel was then charged with CH2Cl2 (0.3 mL) and 



































allyl bromide 3.23 (68 mg, 0.063 mmol) was charged with CH2Cl2 (0.3 mL) and cooled to 
0 ºC. 2,6-di-t-butylpyridine (82 µL, 0.378 mmol), and Cl3SiH (7.7 µL, 0.076 mmol) were 
added sequentially.  The solution was mixed, then transferred dropwise via syringe to the 
0 ºC CuBr/Et3N solution. The resulting mixture was stirred for 5 h at 0 ºC. To a solution 
of (R,R)-3.49 (15.6 mg, 0.063 mmol) and TBAB (4 mg, 0.0126 mmol) in CH2Cl2 (0.2 
mL) was added DBU (28.3 µL, 0.189 mmol). This mixture was dropwise via syringe to 
the reaction mixture, rinsing with CH2Cl2 (0.1 mL). The resulting solution was stirred 2 h 
at 0 ºC. The silane solution was then re-cooled to –78 ºC and a solution of freshly 
prepared aldehyde 3.2 (44 mg, 0.378 mmol) in CH2Cl2 (0.2 mL) was added. The reaction 
was stirred at -10 ºC for 12 h. The reaction mixture was cooled to –40 ºC, treated with 
TBAF3H2O (76 µL, 1M in THF) and stirred 1 h at 0 ºC.  The mixture was then passed 
through a silica plug with EtOAc and concentrated to give the crude product. Purification 
by flash column chromatography (0% à 5% EtOAc/Hexanes) on pH 7 buffered silica gel 
afforded alcohol 3.48 as a clear oil (44 mg, 0.039 mmol, 62% yield). 1H NMR (400 
MHz, C6D6) δ 6.63 (d, J = 14.7 Hz, 1H), 6.40 (dd, J = 14.8, 4.2 Hz, 1H), 5.23 – 5.00 (m, 
5H), 4.52 – 4.45 (m, 1H), 4.31 – 4.24 (m, 2H), 4.00 – 3.84 (m, 3H), 3.73 – 3.68 (m, 1H), 
3.67 – 3.45 (m, 8H), 3.21 – 3.13 (m, 5H), 2.98 (d, J = 3.6 Hz, 1H), 2.63 – 2.49 (m, 3H), 
2.33 – 2.23 (m, 2H), 2.07 – 1.26 (m, 9H), 1.17 (t, J = 8.1 Hz, 9H), 1.12 – 0.99 (m, 27H), 
0.99 – 0.57 (m, 24H), 0.23 (s, 3H), 0.14 (s, 3H). HRMS (APCI+) calcd for 





 To a solution of diol 3.30 (392 mg, 0.432 mmol) in CH2Cl2 (9 ml) was added 
sequentially Et3N (0.60 ml, 4.32 mmol), PPh3 (566 mg, 2.16 mmol) and CCl4 (0.84 ml, 
8.64 mmol). The reaction was stirred overnight at rt and quenched by the addition of 
NaHCO3 (sat. aq) (10 mL). The layers were separated and the aqueous layer was extracted 
with Et2O (2 x 7 ml). The combined organic layers were dried over Na2SO4, filtered, and 
concentrated. Purification by flash column chromatography (0 à 2% EtOAc/Hexanes 
with 1% Et3N) on silica gel afforded dichloride 3.50 as a colorless oil (357 mg, 0.379 
mmol, 87% yield). [α]D24 +31.5º (c 1.00, CH2Cl2). IR (ATR) 2952, 2876, 1648, 1459, 
1415, 1377, 1238, 1078 cm-1. 1H NMR (500 MHz, C6D6) δ 5.29 (d, J = 1.5 Hz, 1H), 5.10 
(s, 1H), 4.39 (d, J = 11.9 Hz, 1H), 4.23 – 4.17 (m, 2H), 3.98 – 3.94 (m, 1H), 3.86 (s, 1H), 
3.57 – 3.48 (m, 3H), 3.46 (d, J = 10.6 Hz, 1H), 3.18 (td, J = 6.5, 2.1 Hz, 2H), 3.12 (s, 3H), 
2.79 (dd, J = 13.8, 2.8 Hz, 1H), 2.45 (dd, J = 13.7, 8.7 Hz, 1H), 2.25 (dd, J = 15.2, 3.7 Hz, 
1H), 1.96 – 1.91 (m, 1H), 1.68 – 1.50 (m, 5H), 1.14 (t, J = 8.0 Hz, 9H), 1.11 – 1.04 (m, 
30H), 0.97 (d, J = 7.2 Hz, 3H), 0.84 – 0.70 (m, 18H), 0.21 (s, 3H), 0.15 (s, 3H). 13C 
NMR (126 MHz, C6D6) δ 144.12, 128.59, 115.64, 101.65, 81.02, 80.61, 77.65, 76.90, 
71.62, 71.28, 67.33, 49.41, 46.94, 44.85, 40.19, 38.96, 37.54, 33.09, 32.46, 30.28, 26.16, 
23.99, 18.40, 16.11, 10.68, 7.50, 7.47, 7.38, 6.23, 6.18, 6.13, -4.09, -4.56. HRMS (ESI+) 






























 In an argon-atmosphere glovebox, copper (I) bromide (2.5 mg, 0.017 mmol) was 
placed in a vial with a stir bar.  The vial was capped with a septum and transferred out of 
the glove box.  The vessel was then charged with CH2Cl2 (0.3 mL) and Et3N (13.5 µL, 
0.097 mmol, 1.4 equiv) and cooled to 0 ºC. In a separate vial under Ar atmosphere, 
dichloride 3.50 (65 mg, 0.069 mmol) was charged with CH2Cl2 (0.3 mL) and cooled to 0 
ºC. 2,6-di-t-butyl pyridine (89.5 µL, 0.414 mmol) and Cl3SiH (8.4 µL, 0.083 mmol) were 
added sequentially.  The solution was mixed, and then transferred dropwise via syringe to 
the 0 ºC CuBr/Et3N solution.  The dichloride vial was then rinsed with CH2Cl2 (0.1 mL), 
this solution was added to the reaction flask, and the resulting mixture was stirred 5 h at 0 
ºC. Additional Cl3SiH (1.4 µL, 0.014 mmol) was added dropwise to the reaction flask, 
and the resulting mixture was stirred 4 h at 0 ºC. A solution of (R,R)-3.49 (17.1 mg, .069 
mmol), TBAB (4.5 mg, 0.014 mmol) and DBU (31 µL, 0.207 mmol) in CH2Cl2 (0.2 mL 
+ 0.1 mL rinse) was then added dropwise via syringe to the reaction mixture. The 
resulting mixture was stirred 2 h at 0 ºC.  The silane solution was then cooled to –78 ºC 
and the freshly prepared chlorodiene aldehyde 3.2 (48.3 mg, 0.414 mmol) in CH2Cl2 
(0.25 mL) was added dropwise.  The reaction was then warmed to -10 ºC and stirred for 
12 h. The reaction mixture was treated with TBAF3H2O (83 µL, 1M in THF) and stirred 
2 h at 0ºC.  The mixture was then passed through a pH 7 buffered silica plug with EtOAc 
and concentrated to give the crude product.  Purification by flash column 



































3.51 as a clear oil (50 mg, 0.049 mmol, 71% yield, 94% yield brsm). [α]D22 +33.9º (c 
1.00, CH2Cl2).  IR (ATR) 3469, 2953, 2876, 1643, 1590, 1459, 1414, 1378, 1238, 1093, 
1006, 835, 727 cm–1.  1H NMR (500 MHz, C6D6) δ 6.64 (d, J = 14.8 Hz, 1H), 6.42 (dd, J 
= 14.8, 4.2 Hz, 1H), 5.18 (s, 1H), 5.11 (s, 1H), 5.07 (s, 2H), 4.52 – 4.45 (m, 1H), 4.23 – 
4.17 (m, 1H), 3.93 (d, J = 3.1 Hz, 1H), 3.86 (s, 1H), 3.73 – 3.68 (m, 1H), 3.62 – 3.56 (m, 
3H), 3.18 (t, J = 6.5 Hz, 2H), 3.13 (s, 3H), 2.98 (d, J = 3.6 Hz, 1H), 2.62 (d, J = 6.7 Hz, 
2H), 2.55 (dd, J = 13.5, 3.1 Hz, 1H), 2.33 – 2.24 (m, 2H), 2.07 – 1.98 (m, 1H), 1.70 (d, J 
= 14.8 Hz, 2H), 1.64 – 1.45 (m, 5H), 1.31 – 1.21 (m, 7H), 1.17 (d, J = 7.8 Hz, 9H), 1.13 – 
1.04 (m, 30H), 0.95 (d, J = 7.4 Hz, 3H), 0.91 – 0.68 (m, 26H), 0.24 (s, 3H), 0.15 (s, 3H). 
13C NMR (126 MHz, C6D6) δ 145.7, 138.9, 138.1, 125.8, 114.4, 113.9, 101.2, 82.3, 79.4, 
77.0, 76.2, 71.2, 70.9, 70.4, 67.0, 46.7, 46.5, 44.4, 39.7, 38.6, 34.6, 32.7, 32.0, 31.6, 30.1, 
29.0, 25.6, 25.3, 23.6, 22.7, 18.0, 16.3, 13.9, 11.3, 10.3, 7.2, 7.0, 6.9, 5.8, 5.6, 5.5, -4.1, -






 A solution of 2,6-lutidine (268 µL, 2.30 mmol) and TBS-OTf (121 µL, 0.69 
mmol) in THF (4.6 mL) was pre-mixed at room temperature for 15 min, then slowly 
added via syringe into a -78 ºC solution of alcohol 3.51 (238 mg, 0.23 mmol) in THF (23 






























aq) (50 mL) and extracted with Et2O (3 x 50 mL). The combined extracts were washed 
with brine (50 mL), dried over Na2SO4, filtered, and concentrated. Purification by flash 
column chromatography (0% à 2% EtOAc/Hexanes) on pH 7 buffered silica gel gave 
TBS ether 3.52 as a colorless oil (237 mg, 90% yield). [α]D25 +31.2º (c 1.00, CH2Cl2).  IR 
(ATR) 2953, 2876, 1646, 1590, 1461, 1415, 1378, 1250, 1112, 1079, 1005, 833, 729 cm–
1. 1H NMR (500 MHz, C6D6) δ 6.56 – 6.41 (m, 2H), 5.23 – 5.10 (m, 3H), 5.07 (s, 1H), 
4.52 (q, J = 6.1 Hz, 1H), 4.23 (d, J = 7.9 Hz, 1H), 3.98 – 3.92 (m, 1H), 3.89 (s, 1H), 3.63 
– 3.44 (m, 4H), 3.17 (d, J = 12.7 Hz, 5H), 2.79 – 2.29 (m, 5H), 2.02 – 1.92 (m, 1H), 1.74 
(t, J = 14.9 Hz, 1H), 1.67 – 1.52 (m, 4H), 1.22 – 1.01 (m, 56H), 0.98 (t, J = 7.2 Hz, 3H), 
0.87 – 0.74 (m, 18H), 0.31 – 0.09 (m, 12H). 13C NMR (126 MHz, C6D6) δ 144.0, 138.5, 
128.2, 126.2, 115.5, 114.7, 101.3, 81.4, 80.7, 77.6, 77.3, 71.8, 71.4, 71.2, 66.9, 46.6, 46.1, 
44.5, 40.1, 38.9, 32.3, 32.1, 30.1, 26.1, 25.8, 23.6, 18.2, 18.0, 15.7, 10.3, 7.5, 7.4, 7.3, 6.3, 
6.2, 6.1, 5.4, -4.1, -4.3, -4.5, -4.6 HRMS (ESI+) calcd for [C57H114Cl2O8Si5NH4+] 




 TBS ether 3.52 (235 mg, 0.206 mmol) was dissolved in MeCN (11.1 mL) and 
MeOH (1.2 mL). To this solution was added i-Pr2NEt (72 µL, 0.413 mmol), NaI (458 
mg, 3.08 mmol), and PPh3 (2.16 g, 8.23 mmol). The resulting mixture was heated at 

































was added. The reaction was heated to reflux for 8 h. The reaction was cooled to rt and 
concentrated. The residue was suspended in CH2Cl2 and filtered through a cotton plug, 
washing with CH2Cl2 (3X). The filtrate was concentrated. Purification by flash column 
chromatography (0% à 5% MeOH/CH2Cl2) on pH 7 buffered silica gel afforded Wittig 
salt 3.53 as a yellow foam (274 mg, 0.184 mmol, 92% yield). Spectroscopic data was 
consistent with that previously reported for this compound 
 




 Wittig salt 3.53 (90 mg, 0.06 mmol) was azeotroped with dry benzene (3x) and 
placed under vacuum for 24 h. Aldehyde 3.54 (90 mg, 0.06 mmol) was azeotroped with 
dry benzene (3x) and placed under vacuum for 24 h. The dried Wittig salt was charged 
with dry 10% HMPA/THF solution (0.63 mL) and cooled to -78 ºC. LiHMDS (66 µL, 
0.066 mmol) was added dropwise and the resultant orange solution was stirred 30 min at 


























































added dropwise to the reaction mixture. The yellow solution was allowed to warm to 0 ºC 
over 1 h and stirred at 0 ºC for 1 h. The reaction was quenched by the addition of a 4:1 
mixture of NH4Cl (sat. aq.) and Na2S2O3 (sat. aq.) (5 mL). Et2O (7 mL) was added the layers 
were separated. The aqueous layer was extracted with Et2O (3 x 4 mL) and the combined 
organic layers were washed with NaHCO3(sat. aq) (5 mL) and brine (5 mL), dried over 
MgSO4, filtered and concentrated. Purification by flash column chromatography (10% à 
40% EtOAc/Hexanes, then 0% à 10% MeOH/CH2Cl2) on pH 7 buffered silica gel 
afforded Wittig product 3.55 as a white solid (75 mg, 0.036 mmol, 60% yield). [α]D27 
+8.2º (c 1.00, CH2Cl2).  IR (ATR) 3332, 2957, 2926, 2877, 288, 1636, 1462, 1419, 1372, 
1259, 1080, 1020 cm–1. 1H NMR (500 MHz, C6D6) δ 6.55 – 6.42 (m, 2H), 5.63 (dd, J = 
9.1, 3.5 Hz, 1H), 5.48 – 5.40 (m, 1H), 5.24 – 4.99 (m, 8H), 4.59 – 4.50 (m, 2H), 4.42 – 
4.26 (m, 1H), 4.03 – 3.95 (m, 2H), 3.91 (s, 1H), 3.81 (td, J = 10.9, 5.3 Hz, 1H), 3.67 – 
3.49 (m, 4H), 3.19 (s, 3H), 3.14 (s, 3H), 2.98 (dd, J = 9.1, 7.0 Hz, 1H), 2.93 (dd, J = 15.8, 
3.9 Hz, 1H), 2.81 (dd, J = 17.1, 7.5 Hz, 1H), 2.77 – 2.65 (m, 2H), 2.61 – 2.48 (m, 3H), 
2.47 – 2.32 (m, 3H), 2.29 – 2.20 (m, 2H), 2.14 – 1.90 (m, 6H), 1.83 – 1.73 (m, 6H), 1.69 
– 1.59 (m, 2H), 1.51 – 1.17 (m, 29H), 1.18 – 1.00 (m, 72H), 0.97 – 0.77 (m, 16H), 0.71 – 
0.60 (m, 5H), 0.29 (s, 12H), 0.26 (s, 3H), 0.18 (d, J = 3.5 Hz, 6H), 0.13 (s, 3H). 13C 
NMR (126 MHz, C6D6) δ 208.47, 170.64, 170.18, 168.84, 148.04, 144.40, 138.91, 
138.89, 135.09, 129.36, 128.59, 126.55, 115.62, 115.11, 113.80, 101.63, 97.64, 97.26, 
81.75, 80.76, 77.76, 77.40, 74.71, 73.19, 71.83, 71.65, 71.31, 70.77, 67.70, 67.01, 64.86, 
64.71, 61.77, 60.00, 55.29, 49.14, 48.93, 47.90, 47.12, 46.98, 45.57, 42.80, 42.73, 42.43, 
42.32, 40.44, 39.36, 39.09, 38.83, 37.73, 34.55, 32.99, 32.20, 32.17, 31.97, 30.33, 30.23, 
29.85, 29.42, 29.29, 28.11, 27.17, 26.21, 23.14, 23.06, 21.36, 20.57, 18.57, 18.42, 18.10, 
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16.23, 14.35, 13.36, 12.99, 12.33, 10.78, 7.72, 7.65, 7.52, 7.46, 7.41, 6.25, 6.23, 6.15, 
1.43, -4.00, -4.22, -4.44, -4.47. HRMS (ESI+) calcd for [C109H203ClO21Si7NH4+] requires 




 Wittig product 3.55 (68 mg, 0.033 mmol) was dissolved in THF (7 mL) and 
cooled to 0 ºC. TBAF3H2O (99 µL, 1M in THF) was added in 6 portions over 1 h and 
stirring was continued at 0 ºC for 3 h. The reaction was quenched by the addition of 
NH4Cl (sat. aq.) (10 mL) and EtOAc (10 mL). The layers were separated and the aqueous 
layer was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed 
with brine (15 mL). The combined aqueous layers were back-extracted with CH2Cl2 (2 x 
10 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. 
Purification by flash column chromatography (0% à 5% MeOH/CH2Cl2) on silica gel 
afforded seco-acid 3.56 as a white solid (46 mg, 0.0274 mmol, 83% yield). [α]D25 +25.4º 
(c 1.00, CH2Cl2).  IR (ATR) 3448, 2951, 2930, 2876, 2860, 1734, 1590, 1551, 1461, 
1371, 1241, 1182, 1144, 1106, 1077, 1027, 1004, 959, 895, 835, 775, 739 cm–1. 1H NMR 



















































2H), 5.24 – 4.93 (m, 12H), 4.58 – 4.35 (m, 2H), 4.34 – 4.24 (m, 4H), 4.02 – 3.87 (m, 3H), 
3.86 – 3.78 (m, 1H), 3.66 – 3.46 (m, 4H), 3.23 – 3.17 (m, 7H), 3.14 (s, 3H), 3.03 – 2.95 
(m, 1H), 2.89 – 2.66 (m, 3H), 2.62 – 1.85 (m, 12H), 1.83 – 1.68 (m, 7H), 1.63 (d, J = 13.4 
Hz, 2H), 1.55 – 1.39 (m, 3H), 1.39 – 0.76 (m, 93H), 0.67 (q, J = 7.9 Hz, 6H), 0.29 – 0.23 
(m, 3H), 0.20 – 0.08 (m, 10H). 13C NMR (126 MHz, C6D6) δ 208.74, 170.11, 169.08, 
167.37, 148.01, 144.36, 143.68, 138.91, 138.89, 135.05, 129.42, 126.55, 115.65, 115.12, 
113.82, 101.69, 97.66, 97.55, 81.72, 81.16, 80.79, 77.82, 77.41, 76.90, 74.85, 73.25, 
72.22, 71.83, 71.69, 71.33, 70.93, 67.67, 66.72, 64.86, 64.62, 61.69, 60.01, 55.75, 55.28, 
53.32, 49.21, 49.01, 47.99, 47.11, 47.05, 45.24, 42.72, 42.41, 42.22, 40.64, 40.44, 39.00, 
38.72, 37.67, 34.37, 32.94, 32.37, 32.23, 32.19, 30.23, 30.16, 30.09, 29.92, 29.85, 29.79, 
29.70, 29.30, 28.11, 27.75, 26.23, 26.21, 25.13, 23.14, 21.33, 18.57, 18.44, 16.20, 16.06, 
14.39, 13.43, 13.05, 10.79, 7.65, 7.52, 7.46, 7.25, 6.37, 6.25, 6.24, 6.15, 6.04, -4.01, -
4.22, -4.41, -4.43, -4.46. HRMS (ESI+) calcd for [C88H155ClO21Si4NH4+] requires m/z 
























































 Seco-acid 2.56 (40 mg, 0.023 mmol) was dissolved in toluene (2.3 mL) and i-
Pr2NEt (0.24 mL, 1.38 mmol) and 2,4,6-trichlorobenzoyl chloride (72 µL, 0.46 mmol) 
were added. This was stirred for 4 h at rt, then diluted with toluene (6.9 mL). The mixture 
was taken up into a 12 mL gas-tight syringe and added to a 90 ºC solution of DMAP (141 
mg, 1.15 mmol) in toluene (34 mL) over 24 h by syringe pump. The vial containing 
starting material which was sealed and stored at 0 ºC was rinsed with toluene (2.3 mL) 
and added to the reaction at over 8 h by syringe pump. The starting material vial was 
rinsed with an additional portion of toluene (2.3 mL) and added to the reaction over 4 h 
by syringe pump. The reaction mixture was allowed to stir at 90 ºC for 20 h. The reaction 
mixture was cooled to rt and diluted with Et2O (50 mL). This was washed with 
NaHCO3(sat. aq) (50 mL) and brine (50 mL). The combined aqueous layers were extracted 
with EtOAc (2 x 50 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated. Purification by flash column chromatography (10% à 40% 
EtOAc/Hexanes) on silica gel afforded lactone 3.57 as a white solid (31 mg, 0.0186 
mmol, 81% yield). [α]D24 +23.9º (c 1.00, CH2Cl2).  IR (ATR) 2928, 2876, 2856, 1735, 
1647, 1583, 1550, 1461, 1370, 1246, 1143, 1110, 1029, 1005, 961, 891, 835 775, 740 
cm–1.  1H NMR (500 MHz, C6D6) δ 6.55 – 6.26 (m, 3H), 5.70 (d, J = 10.4 Hz, 1H), 5.41 
(q, J = 7.7 Hz, 2H), 5.23 – 4.93 (m, 14H), 4.84 (q, J = 15.7 Hz, 1H), 4.41 (dq, J = 22.9, 
12.2, 9.5 Hz, 6H), 4.03 – 3.74 (m, 5H), 3.64 – 3.39 (m, 5H), 3.28 – 3.05 (m, 10H), 2.68 
(s, 1H), 2.61 – 2.46 (m, 5H), 2.45 – 2.05 (m, 5H), 2.11 – 1.54 (m, 16H), 1.55 – 0.54 (m, 
162H), 0.32 – -0.02 (m, 17H). 13C NMR (126 MHz, C6D6) δ 208.78, 171.46, 170.32, 
168.49, 148.19, 143.48, 142.76, 139.04, 138.89, 134.50, 130.01, 128.59, 126.53, 126.49, 
126.38, 117.17, 116.20, 115.64, 115.21, 113.41, 101.80, 101.71, 97.70, 97.62, 97.07, 
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96.97, 80.93, 80.11, 79.69, 79.22, 78.87, 76.82, 75.03, 73.16, 73.06, 72.79, 72.33, 72.15, 
71.71, 71.53, 71.31, 71.21, 70.43, 67.04, 65.41, 64.60, 63.51, 60.33, 55.74, 55.33, 51.42, 
48.36, 48.06, 46.97, 46.56, 46.39, 45.66, 44.17, 42.51, 40.45, 40.30, 39.32, 38.96, 38.62, 
38.44, 38.19, 37.84, 36.85, 36.13, 34.83, 33.35, 32.97, 32.78, 32.52, 32.38, 32.32, 30.55, 
30.24, 29.87, 29.56, 27.68, 26.19, 26.10, 25.56, 25.05, 23.16, 21.47, 20.63, 18.51, 18.33, 
14.63, 14.42, 13.86, 12.68, 10.80, 10.64, 7.73, 7.55, 7.21, 6.18, -4.13, -4.28, -4.47, -4.73. 





 Lactone 3.57 (26 mg, 0.015 mmol) was dissolved in MeCN (1.08 mL) and cooled 
to -20 ºC. A freshly prepared solution of HF in MeCN (1.08 mL) [prepared by mixing 
48% aqueous HF (1.25 mL) and MeCN (5 mL)] was added over 2 h by syringe pump at -
20 ºC. The reaction was allowed to stir an additional 18 h at this temperature. The 
reaction was quenched by the dropwise addition of Et3N (2.53 mL) and warmed to rt. The 
reaction mixture was diluted with a 2:1 mixture of EtOAc/CH2Cl2 (13 mL), then washed 




















































extracted with a 2:1 mixture of EtOAc/CH2Cl2 (2 x 13 mL). The combined organic layers 
were dried over Na2SO4, filtered and concentrated. Purification by flash column 
chromatography (0% à 5% MeOH/CH2Cl2) on silica gel afforded spongistatin 1 analog 
3.58 as a white solid (15 mg, 0.0125 mmol, 83% yield). [α]D22 +18.2º (c 0.50, MeOH).  
IR (ATR) 3435, 2926, 2851, 1735, 1653, 1580, 1551, 1436, 1384, 1233, 1177, 1093, 
1059, 894 cm–1. 1H NMR (500 MHz, CD3CN) δ 6.50 – 6.34 (m, 1H), 6.25 – 6.06 (m, 
1H), 5.45 (d, J = 6.9 Hz, 2H), 5.36 (s, 1H), 5.33 – 5.11 (m, 3H), 5.07 (s, 1H), 4.97 – 4.79 
(m, 6H), 4.81 – 4.67 (m, 1H), 4.48 – 4.22 (m, 3H), 4.21 – 4.08 (m, 2H), 4.08 – 3.96 (m, 
1H), 3.93 – 3.47 (m, 4H), 3.47 – 3.31 (m, 1H), 3.27 (d, J = 18.9 Hz, 6H), 3.19 – 3.03 (m, 
1H), 3.03 – 2.69 (m, 3H), 2.66 – 2.47 (m, 1H), 2.44 – 2.30 (m, 1H), 2.30 – 2.22 (m, 2H), 
1.87 – 1.78 (m, 4H), 1.73 – 1.45 (m, 6H), 1.28 (d, J = 13.7 Hz, 11H), 1.14 (dd, J = 7.0, 
2.7 Hz, 3H), 1.09 – 0.97 (m, 7H), 0.88 (d, J = 7.1 Hz, 1H), 0.84 – 0.73 (m, 6H). 13C 
NMR (126 MHz, CD3CN) δ 210.67, 172.78, 171.60, 170.08, 148.06, 144.10, 139.24, 
138.97, 135.80, 128.97, 126.86, 126.81, 99.25, 99.18, 99.13, 97.99, 81.09, 81.01, 80.34, 
78.82, 78.56, 77.76, 74.86, 73.84, 73.16, 73.00, 71.49, 70.55, 69.38, 69.27, 69.16, 67.04, 
64.71, 63.43, 62.58, 62.32, 60.69, 56.11, 55.51, 50.62, 48.14, 46.81, 45.11, 44.28, 44.04, 
43.81, 42.94, 42.21, 40.41, 40.29, 40.14, 39.73, 39.64, 37.36, 37.29, 37.23, 36.77, 34.49, 
33.78, 33.19, 32.64, 32.51, 30.35, 30.15, 30.07, 29.40, 27.72, 27.06, 23.39, 21.76, 21.00, 
14.39, 13.10, 12.80, 12.24, 11.29. HRMS (ESI+) calcd for [C63H95ClO20Na+] requires 
m/z 1229.6003, found 1229.5991. 
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